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a b s t r a c t
Targeted therapies and the consequent adoption of “personalized” oncology have achieved notable
successes in some cancers; however, signiﬁcant problems remain with this approach. Many targeted
therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few
disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant
immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not
reliant upon the same mechanisms as those which have been targeted). To address these limitations, an
international task force of 180 scientists was assembled to explore the concept of a low-toxicity “broadspectrum” therapeutic approach that could simultaneously target many key pathways and mechanisms.
Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects
of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide
range of high-priority targets (74 in total) that could be modiﬁed to improve patient outcomes. For these
targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were
phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for
known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed
evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the
relationships revealed potentially complementary effects, and the remainder had no known relationship.
Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships.
These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This
novel approach has potential to be relatively inexpensive, it should help us address stages and types of
cancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for future
research is offered.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

1. Introduction
Cancer is a source of signiﬁcant and growing mortality worldwide, with an increase to 19.3 million new cancer cases per year
projected for 2025. More than half of cancer cases and mortality
occur in low- and middle-income countries, and these proportions
are expected to increase by 2025 [1]. Current treatments for cancer
include surgery, radiotherapy and systemic treatments comprising cytotoxic chemotherapy, hormonal therapy, immunotherapy,
and targeted therapies [2]. Cancer continues to stymie clinical
treatment efforts, however, and the search for effective therapies
continues.
This capstone paper describes the methods and results of a substantial effort by a large international group of biochemical and
medical researchers, operating under the name of “The Halifax
Project,” sponsored by a non-proﬁt organization, Getting To Know
Cancer. It summarizes and draws together material from a series of
reviews on the hallmarks of cancer, presented in this special issue
of Seminars in Cancer Biology, to present a conceptual framework
for a new approach to cancer prevention and therapeutics. This
approach involves the targeting of many speciﬁc high-priority anticancer mechanisms and pathways within a more comprehensive
model of treatment and care. We refer to this as a “broad-spectrum”

approach (i.e., an approach aimed at a broad spectrum of important mechanisms and pathways) [3]. The broad-spectrum approach
involves combinations of multiple low-toxicity agents that can collectively impact many pathways that are known to be important
for the genesis and spread of cancer. By making extensive use of
chemicals from plants and foods that have already been studied or
utilized for cancer prevention and treatment, this approach offers a
compelling rationale for addressing the underlying biology of cancer while being efﬁcacious, non-toxic and cost-effective. We come
together in the belief that a broad-spectrum approach of this type,
in the context of a therapeutic environment including conventional
treatment and attentive to optimal health, would provide genuine
beneﬁt in clinical outcomes for cancer patients. In this paper we
describe the rationale for broad-spectrum therapeutics, detail the
methods of the Halifax Project, summarize potential targets and
agents related to eleven hallmark features of cancer, propose a
research model for the development of broad-spectrum therapies,
and call for action to advance this research model.
1.1. Rationale for broad-spectrum approach
Primary motivations for the development of a broad-spectrum
approach stem from the distinct limitations that are evident in

S280

K.I. Block et al. / Seminars in Cancer Biology 35 (2015) S276–S304

Fig. 1. Diagrammatic representation of removal of susceptible cells by a targeted cancer therapy resulting in disease remission, which leaves genetically heterogeneous
resistant cells to proliferate, resulting in relapse.

many current targeted therapies and the personalized medicine
paradigm. Molecular target therapies represent a signiﬁcant
advance in the treatment of cancer. They include drugs such as
imatinib, an inhibitor of the tyrosine kinase enzyme BCR-ABL,
which has made chronic myelogenous leukemia a more manageable disease, and inhibitors of vascular endothelial growth factor
receptor (VEGFR), such as sunitinib, sorafenib and bevacizumab,
used in renal and colon cancers [2]. Other important treatments
based on tumor-speciﬁc targets are now in use, including examples such as epidermal growth factor receptor (EGFR) inhibitors
(geﬁtinib, erlotinib) used in lung cancer, and the Her2 inhibitor
trastuzumab used in breast cancer. Another approach is the synthetic lethal model [4] exempliﬁed by research on poly ADP ribose
polymerase (PARP) inhibition, in which mutational loss of one
or more redundant components of a cell survival pathway in
tumorigenic cells confers selective sensitivity to drugs that target
remaining pathway components.
These drugs target cells bearing one, or at most a few mutated
gene products or other abnormalities not found on normal cells.
In the therapeutic context, the action of the targeted agents can
efﬁciently address malignant cells, without some of the effects on
normal cells notorious in cytotoxic chemotherapy. This enables
therapeutic responses and remissions. Over time, however, the
genetic heterogeneity of tumors increases, engendering resistance
to treatment. Resistant cells drive the emergence of increasingly
aggressive disease, through clonal expansion and clonal evolution (Fig. 1). Epigenetic modiﬁcations, heritable cellular changes
not caused by alterations to DNA sequences, but by alterations
such as methylation of DNA or modiﬁcation of the histone protein
associated with DNA, may also affect patterns of gene expression and drive cancers [5]. Relapses often occur after only a few
months, and tumors reappear, sometimes in exactly the same areas
in which they originated [6]. Moreover, targeted agents are not
without serious side effects, such as treatment-related mortality
with bevacizumab and cardiopulmonary arrest with cetuximab.
Meta-analysis of trials of recently approved cancer drugs including targeted therapies versus older drugs showed increased rates
of grades 3 and 4 toxicity (OR = 1.52), treatment discontinuation
(OR = 1.33) and toxic deaths (OR = 1.40) [7]. This worsening of
adverse effects has gone in large part unacknowledged.
The efﬁcacy shown to date with targeted therapies, aside
from now-established treatments such as bevacizumab and
trastuzumab, is nevertheless still limited. Sunitinib, for instance,
extends overall survival by 4.6 months in renal cancer compared
with the previous treatment of interferon-␣ [8]. While statistically
signiﬁcant, this degree of improvement is small comfort to afﬂicted
patients, and challenges the extraordinary monetary investment
in drug development as well as costs to the medical system that
targeted therapies represent. The MOSCATO 01 trial of molecular
triage was able to treat 25 of 111 patients with a variety of advanced
cancers using therapies targeted to genomic alterations assessed
from tumor biopsies [9]. Of these, 5 patients (20%) experienced
partial response and 56% had stable disease. Based on the entire

population of 111 patients, this is a partial response of less than 5%,
suggesting limited efﬁcacy to date, an outcome also seen in some
other studies [10]. On a more hopeful note however, a combination of pertuzumab with trastuzumab and the chemotherapy agent
docetaxel was recently found to extend overall survival among the
subset of breast cancer patients whose tumors express Her-2 by
15.7 months [11].
Interestingly, harnessing the body’s immune response against
the tumor can also result in impressive durable clinical responses,
perhaps because the immune system is a paragon of adaptability and can deal with changes in the mutational landscape of
cancer to prevent escape from the therapeutic effect. Immunomodulatory antibodies recently licensed in the United States include
ipilimumab as well as nivolumab and pembrolizumab, neutralizing two different inhibitory pathways that block antitumor T cell
responses. These agents have achieved some successes in treating
late stage cancers refractory to essentially any other treatments
[12]. But even with these agents, response rates are still low and
predicting who will respond is an unsolved challenge [13,14].
Many of these therapies are somewhat narrowly described as
“personalized” because patients’ tumors must be tested for speciﬁc mutations to stratify patients to the correct therapy. Viewed
in the larger context of individual biological variation, of course,
speciﬁc mutations drive only the smallest degree of personalization. Truly personalized treatment approaches can be seen to
include a much more comprehensive assessment of genetic and
even lifestyle factors, such as nutritional, biobehavioral (stress
management) strategies, and exercise habits, along with other
host variables such as inﬂammation and immune status. Such an
approach to personalizing treatment can be found in the systematic
practice of integrative medicine, which played a signiﬁcant role in
the development of this model of broad-spectrum cancer therapy.
Some deﬁnitions of integrative medicine stress simply the inclusion
of complementary and alternative therapies alongside orthodox
treatment [15]. A more relevant deﬁnition emphasizes a patientcentered, multi-intervention treatment paradigm that addresses
the full range of physical, mental, emotional and environmental
inﬂuences, utilizing an array of disciplines including diet, mindbody and physical activity therapies in addition to conventional
therapies and dietary supplements to support optimal health [16],
based on laboratory testing that enables comprehensive personalization.
The stratiﬁcation of patients for these targeted and personalized therapies poses practical challenges. As indicated earlier,
over 50% of the increase in cancer incidence by 2025 is projected
to occur in the developing world [1]. As industrialization develops in lower-income countries, occupational cancers are expected
to increase, potentially aggravating this situation [17]. Cancer
treatment in many of these countries is already becoming a socialeconomic challenge due to the expense and medical infrastructure
required [18], and the new generation of treatments may further
strain local resources. Currently, the platforms used for testing
to personalize regimens include whole exome or whole genome
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sequencing, whole transcriptome sequencing, and comparative
genomic hybridization with still others in development. It is likely
that such tests, and related expense, will proliferate in the future.
Managing treatment toxicity is also a taxing and complex problem,
as these toxicities necessitate additional medical interventions.
The expense of the new targeted therapies is also concerning.
Eleven of twelve drugs approved by the US Food and Drug Administration (US FDA) in 2012 were priced above $100,000 US per year
per patient – perhaps not surprisingly in view of the accelerating
costs of drug development [19]. Clinicians have drawn attention
to these high costs: in 2013 more than 100 experts in chronic
myeloid leukemia coauthored a paper calling for lower prices
and broader access to these drugs [20]. The excessive costs have
resulted in drugs not being approved for use by national or regional
governments where cost-beneﬁt analyses ﬁgure in approval processes [21]. While costs are expected to decrease after expiration
of patents on the drugs, the costs for treatment in low- or middleincome countries may continue to be problematic. The potential
for unsupportable ﬁnancial stress on health systems challenges the
research community to explore other treatment models that can
be more sustainable in the face of the worldwide increase in cancer
incidence.
The broad-spectrum approach that we describe here is primarily
intended to address the two major issues of therapeutic resistance and cost. It is based on many of the insights of genomic
sequencing in cancers. We now know that cancers harbor significant genetic heterogeneity, even within a single patient [6]. Based
on this heterogeneity, cancers routinely evolve resistance to treatment through switching from one growth pathway to another [22].
The proposed strategy employs the basic principles of rational drug
design, but aims to stem cancer growth by precisely targeting many
growth pathways simultaneously. Some effort is now being made
in combining targeted agents so that more than one pathway can
be affected, but lack of therapeutic success, signiﬁcant toxicity and
costs make this a challenge [23–26].
We see the broad-spectrum approach as one that is complementary to existing therapies, preferably within the context of a
genuinely integrative clinical system. Clinical situations in which
such an approach might prove useful include (a) as a follow-up
maintenance plan to conventional adjuvant treatment; (b) in situations of rare cancers and disease stages for which no accepted
treatments exist; (c) for patients who do not tolerate conventional chemotherapy, hormonal therapy or targeted therapies; (d)
for patients who experience relapse or progression after targeted
treatment; (e) in hospice or palliative care patients where low- or
non-invasive strategies are a legitimate and humane option; and (f)
in situations in which high-cost agents cannot be obtained. Because
of continuous heterogeneity among cancer cells, and their propensity for genomic instability, even a broad-spectrum approach is
unlikely to cause complete remission. However, the design of this
approach posed a substantial theoretical challenge, for which we
chose to use the hallmarks of cancer as a broad organizing framework.
1.2. Hallmarks of cancer as a framework for developing
broad-spectrum therapeutics
Hanahan and Weinberg ﬁrst published their concept of the
hallmarks of cancer in 2000 [27]. The hallmarks “constitute
an organizing principle that provides a logical framework for
understanding the remarkable diversity of neoplastic diseases.”
This framework encompasses the biological capabilities that
cells acquire during the development of cancers that allow
them to become malignancies as we know them. Six hallmarks
were proposed in the 2000 publication: sustained proliferative
signaling, evading growth suppressors, activating invasion and
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metastasis, enabling replicative immortality, inducing angiogenesis and resisting cell death. The concept of the hallmarks became
widely recognized and inﬂuential. In 2011, Hanahan and Weinberg
expanded on the initial hallmarks to include other areas of cancer
biology that they felt were equally important [28]. They pointed out
two enabling characteristics critical to the ability of cells to acquire
the six hallmarks, and two new hallmark capabilities. They also singled out the crucial nature of the complex tumor microenvironment
in the appearance of the cancer phenotype. The enabling characteristics are genomic instability and tumor-promoting inﬂammation;
the new hallmarks are deregulating cellular energetics and avoiding immune destruction.
The hallmarks framework helps to deﬁne domains in which high
priority targets can be identiﬁed for therapeutic targeting. Hanahan
and Weinberg point out that agents are in development that target
each of the hallmarks. They also note, however, that in response to
targeted therapy, cancers may reduce their reliance on a particular
hallmark capability, such as angiogenesis, and instead heighten the
activity of another capability, such as invasion and metastasis [29].
This reaction has been clinically veriﬁed in the case of glioblastoma
[30].
Another model, which was proposed by Vogelstein et al. in
2013 [6], also attempts to describe the mechanisms and pathways that are relevant to many cancers. In this model, “driver”
genes that drive cancer growth are distinguished from “passenger”
mutations found in cancer cells that impart no growth advantage. Twelve major signaling pathways that drive cancer growth
have been elucidated, including signal transducers and activators
of transcription (STAT), Notch, DNA damage control and 9 others.
These pathways are classiﬁed into three cellular processes underlying tumor growth: cell survival, cell fate and genome maintenance.
Individual patients with the same cancer can have mutations on different pathways, leading to inter-patient heterogeneity. Yet within
each patient there is also substantial heterogeneity, both within
each patient’s primary tumor, and among and within metastases,
with signiﬁcance for treatment strategies. For instance, the smallest metastases visible through medical imaging may already have
thousands of cells that harbor mutations rendering them resistant
to current drugs [31].
Cancer mutations, moreover, are not simply a series of isolated
targets. Beneath the surface of the cancer genome is a notably
complex cellular signaling network, ﬁlled with redundancies. The
elucidation of rational therapeutic combinations requires dynamic
mechanistic models that reach beyond simple targeting [32]. What
propels growth, dissemination and thus ineffective treatment and
drug resistance actually appears not to be pathways acting in isolation but interconnected, multidirectional and dynamic networks
[33]. Even sorafenib, which inhibits multiple kinases, is susceptible
to the rapid development of resistance deriving from crosstalk in
pathways such as phosphatidylinositide 3-kinase/protein kinase B
(PI3K/Akt) and Janus kinase (JAK)-STAT, hypoxia-induced signaling
or the epithelial-to-mesenchymal transition (EMT) [34]. Conventional drug discovery programs are now contemplating systems
biology approaches aimed at furthering the network approach
to pharmacology. The interdependence of cytokines, chemokines,
growth factors, transcription factors, and their resulting proteomes,
together with their relevance to cancer prevention and treatment
[35], makes systems biology approaches most attractive [36]. This
realization makes the signiﬁcance of a broad-spectrum approach
to cancer of even greater importance.
Clinicians as well as researchers recognize the importance of
heterogeneity in cancer. A least one clinical center recognizes
the signiﬁcance of this heterogeneity, and intervenes with broadspectrum approaches to respond to it. In a 2009 book, Life Over
Cancer, based on a clinic in operation since 1980, Block lays out
a model of nutraceutical-based targeting of nine “pathways of
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progression” and six metabolic factors impacting the challenges
faced by all cancer patients [3]. The nine growth pathways are
proliferation, apoptosis, treatment resistance, immune evasion,
angiogenesis, metastasis, cell-to-cell communication, differentiation and immortality. Multiple targeting of these pathways with
natural products is used to simultaneously address multiple interconnected growth pathways. Comprehensive molecular proﬁling
maps patients’ growth pathways and provides for relevant natural product intervention. The six metabolic “terrain factors” are
oxidation, inﬂammation, glycemia, blood coagulation, immunity
and stress chemistry. Terrain-focused interventions are tailored
to patients’ laboratory test results, which are monitored regularly
to guide therapeutic modiﬁcation. Interventions include elimination of maladaptive lifestyle patterns, adjusting exercise habits,
improving diet, implementing biobehavioral strategies to diminish adverse consequences of unabated stress/distress, and using
natural products and medications that affect speciﬁc targets such
as C-reactive protein (CRP) [37], interleukin-6 (IL-6), nuclear factor -beta (NF-B) [38], prostaglandin E2 and leukotriene B4 [39]
for inﬂammation. Clinical observations and literature review suggest potential efﬁcacy for this system in breast cancer (including a
near-doubling of survival time of breast cancer patients in integrative care) and potentially other cancers [40,41]. Essentially, Block’s
clinical model systematically addresses multiple targets and pathways through a speciﬁc and selective broad-spectrum approach to
treatment. While this system was developed in clinical practice,
quite independently from the discussion of hallmarks and enabling
characteristics by Hanahan and Weinberg, the conceptual overlap
is obvious. That these concepts have already been used in clinical
treatment provides powerful support for the viability of a carefully
designed broad-spectrum approach.
The model we propose to use to develop a sound framework
for a broad-spectrum approach recognizes these broad areas of
conceptual overlap and agreement, and can be considered to best
align with the hallmarks of cancer framework [27]. Our framework
encompasses the molecular and metabolic diversity of malignancy
recognized in Hanahan and Weinberg’s hallmarks, Vogelstein’s 12
growth pathways, Block’s pathways of progression and terrain factors, and other emerging research. For the purposes of this project,
we treat the 6 hallmarks, 2 enabling characteristics, 2 emerging
hallmarks, and the tumor microenvironment equally as hallmarks
of malignancy. From a design standpoint, each of these individual
areas encompasses an important aspect of cancer’s biology, so each
was seen as important to consider for a therapeutic approach aimed
at a wide range of high priority targets.
In mid-2012, the framework for this project and approach were
shared with Douglas Hanahan. He later independently provided
support for this type of approach in a paper, “Rethinking the war
on cancer” [42]. Using a military metaphor, he suggests a threedimensional cancer “battlespace” plan that attacks cancer in a
full-scale war rather than individually targeted skirmishes. The ﬁrst
dimension is disruption of cancer’s many capabilities, speciﬁcally
those ﬁguring in the hallmarks. Rather than just removing one capability, as targeted therapies do, he explains that an ideal approach
should target all the hallmark capabilities. The second dimension is
defense against cancer’s armed forces, implying speciﬁc targeting
of the accessory cell types in the tumor microenvironment, such
as tumor-promoting inﬂammatory cells. The third dimension represents the multiple battleﬁelds of cancer: primary tumor, tumor
microenvironment, lymph and blood vessels through which tumors
disseminate, draining lymph nodes and distant organs. This dimension suggests still more targets.
A rapidly developing sub-discipline in oncology is the application of genetic and immune analysis of tumor tissue and the
concomitant use of personalized therapies and prescriptions. These
analyses allow better stratiﬁcation of patients to treatments and

clinical decision-making [43]. In the case of breast cancer alone,
tests range from Her-2 testing, the basis of trastuzumab treatment
to sophisticated suites of tests that analyze dozens of genes. These
complex analyses assist in treatment decisions based on correlations with clinical outcomes by predicting treatment response, risk
of recurrence and outcome. They suggest the size of the network of
genes that affect just one cancer, and emphasize the signiﬁcance of
a broad-spectrum attack. Clinical utility of these tests is still under
review [44].
Despite impressive progress in genomic and gene expression
proﬁling, however, it is often impossible to fully characterize the
range of immortalized cell variants within any given cancer. The
perspectives offered by Hanahan, Vogelstein and Block, as well as by
the recognition of the network aspects of signaling pathways, however, suggest a larger number of targets may need to be reached.
So the 138 driver genes, together with the 12 signaling pathways
that comprise them, in addition to the molecular contributors to the
hallmarks, and Block’s nine pathways of progression and six terrain
factors, help us delineate some of the most signiﬁcant targets that
should be taken into account in development of a broad-spectrum
approach.

2. Methods
The effort to develop the concept of broad-spectrum targeting
of cancer through a complex combination of agents, emphasizing naturally occurring chemicals, was developed by a non-proﬁt
organization, Getting To Know Cancer, and implemented within
an initiative called “The Halifax Project.” The aim of the project
was to produce a series of reviews of the cancer hallmarks that
could collectively assess and prioritize the many target choices
that exist, and also identify non-toxic chemicals (primarily from
plants or foods) that could safely be combined to produce an optimized broad-spectrum approach that has both prophylactic and
therapeutic potential. To that end, it was envisioned that eleven
teams of researchers would produce reviews on the ten cancer
hallmarks plus the tumor microenvironment, which was treated
as a hallmark for the purposes of this project. Each review was
to describe the hallmark, its systemic and cellular dysfunctions,
and its relationships to other hallmarks. A priority list of relevant
therapeutic targets and corresponding approaches suited to those
targets was requested, along with a discussion of research needed
in the context of goals of the project. Natural compounds were
emphasized because of the growing body of literature that supports the low toxicity and interesting potential that many of these
substances have demonstrated (i.e., as targeted therapeutics or in
cancer prevention), while recognizing the variable effectiveness of
these compounds in human trials as well as the undocumented
safety or frank toxicity concerns with many natural products [45].
In recognition of the network of signaling pathways involved not
only in drug resistance but the interconnection and maintenance of
all the hallmarks, the project implemented a cross-validation step
in the evaluation of targets and approaches. Because of the diversity
of the targets involved in the 11 hallmark areas, it is not unreasonable to suspect that inhibiting or stimulating a target relevant to one
hallmark may have an adverse growth effect or clinically adverse
effect on a target in another hallmark. For instance, reducing DNA
damage is a potential target for counteracting genomic instability. Activation of the immune system can counter DNA damage by
eliminating damaged cells. However, activation of the immune system, while reducing overall levels of DNA damage, can contribute
to chronic inﬂammation [46].
Similar considerations apply to therapeutic approaches. For
instance, triptolide, a component of the Chinese herb Tripterygium
wilfordii, is known to cause apoptosis in cancer cells [47]. Extracts
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of the herb have been used in clinical trials for a variety of inﬂammatory and immune-linked conditions, and have demonstrated
both antiinﬂammatory and immune suppressant activity, raising
concern for its effect on immune evasion [48,49].
To address this issue, a specially designated cross-validation
team was created within the project to evaluate all selected
targets and approaches, i.e., to determine whether the inhibition or activation of targets, and the application of approaches,
would have negative effects on other hallmarks. Each potential
target-hallmark or approach-hallmark interaction was assessed
to determine whether the pair had a complementary interaction
(i.e., the interaction of the target or approach with the hallmark
facilitated anticancer activity), a contrary interaction (i.e., the interaction of the target or approach with the hallmark had a potential
adverse tumor-stimulating or tumor-progression effect), a controversial interaction (i.e., mixed indications of anticancer and
tumor-stimulating effects), or no known relationship. A sample
cross-validation table for dysregulated metabolism approaches can
be accessed as Supplemental Table S1.
It is important to note that the cross-validation team was not
given any restrictions for literature selection for this effort, and
contributing authors were not restricted to cancer-related research.
This approach was taken because it was realized at the outset that
this breadth and speciﬁcity of knowledge does not yet exist in the
literature. As a result, the types and sources of data gathered in this
effort varied considerably, although original studies were consistently favored over review articles. Moreover, many studies that
were cited in this effort considered only a compound’s ability to
instigate or promote an action that mimics a hallmark phenotype
in a manner directionally consistent with changes that have been
associated with cancer. So while we refer to these as anticancer
or tumor-stimulating, the speciﬁcity of these activities and their
implications for cancer treatment cannot and should not be immediately inferred from this database. In other words, the results from
this aspect of the project were only compiled to serve as a starting
point for future research, rather than a conclusive guide to therapy.
Targets or approaches that have a substantial number of
“contrary” assessments are less attractive for inclusion in the
broad-spectrum approach. On the other hand, the use of targets and
approaches that appear to have the potential for multiple complementary interactions is consistent with principles of rational drug
design, and akin to efforts to design “dirty” drugs (a pharmacological term for drugs with multiple targets – as opposed to single
targets – aimed at multidimensional conditions) [50]. Further evaluation of such “dirty” targets and approaches could be undertaken
through more speciﬁc application of network pharmacology, for
which new tools are currently becoming available [51]. The tabulated results, which appear in the individual reviews, are discussed
in a later section of this paper.
The review teams needed for the Halifax Project were formed by
ﬁrst circulating an email to a large number of cancer researchers,
seeking expressions of their interest in participation. The email was
circulated in July 2012 by Getting To Know Cancer, and scientists
were encouraged to submit their details on a dedicated webpage
that offered additional project detail. From the pool of 703 cancer scientists who responded to the email, 11 team leaders were
selected to each lead a group in producing a review of each hallmark, and an additional leader selected for the cross-validation
team. Those leaders were then asked to form their own teams (by
drawing from the pool of researchers who expressed interest in the
project, and from their own circles of collaborators). Ultimately,
12 teams were formed. Team members were each encouraged to
engage a junior researcher as well. This led to fairly large teams but
it allowed us to distribute the effort considerably. Team leaders all
received project participation guidelines; extensive and ongoing
communication from the project leader, Leroy Lowe; copies of the
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relevant papers of Hanahan and Weinberg; and copies of Life Over
Cancer by Block [3] as an example of practical clinical implementation of the broad-spectrum approach. In addition to the 11 teams,
two guest editors, Anupam Bishayee and Keith Block, were selected
for this special issue of Seminars in Cancer Biology in which the team
reviews are published.
The team leaders and other team members who were able to
attend the project workshop met in Halifax, Nova Scotia in August
2013 to discuss the project. Drafts of hallmark team papers were
submitted in advance, and summary presentations made at the
meeting. Other subject matter presentations included presentations on research funding in the natural products area (Jeffrey D.
White, Ofﬁce of Cancer Complementary and Alternative Medicine,
National Cancer Institute) and the concept of driver and passenger genes (Bert Vogelstein, Johns Hopkins). Presentations on
integrative cancer therapeutics made at the meeting are summarized below (Keith Block, Penny Block, Block Center for Integrative
Cancer Treatment). Group discussions were held to facilitate communication among teams and project staff, and to assist teams in
exploring the requirements and rationale for selection of targets
and approaches.
Each hallmark team contained the following specialists: a lead
author with demonstrated expertise in the hallmark area; domain
experts who produced the descriptive review; anticancer phytochemical specialists; oncologists; and support researchers. The
cross-validation team conducted background literature searches on
the submitted targets and compounds from each review team, verifying their activity in relation to the other hallmarks. Results of the
cross-validation effort were tabulated and reviewed by the individual teams. Ambiguous results and areas of disagreement were
reconciled, and the tables were ultimately incorporated into each
hallmark review.
2.1. Selection of targets and approaches
It was assumed from the outset that, in a translational project
aimed at the development of a broad-spectrum approach, there
would be a practical upper limit to the number of potential targets in any given cancer that could be targeted. So each hallmark
team was asked to select and prioritize up to 10 relevant targets for
their hallmark area, bearing in mind that each target would serve
as a starting point for the identiﬁcation of a suitable low-toxicity
approach that might be used to reach that target. In theory, it was
understood that this could lead to as many as 110 targets for the
entire project, and since the teams were also asked to select one
therapeutic approach for each target, a maximum of 110 potential
therapeutic approaches might be selected.
An “approach” was deﬁned in this project as (1) a technique that
will cause the body to respond in a manner that will act on the target
(e.g., fasting, exercise, etc.), or (2) a procedure involving an entity
that can act on the target (e.g., phytochemical, dietary modiﬁcation,
synthetic drug, vaccination with peptides, locally administered
oncolytic virus, etc.). Teams were then asked to identify “favored”
approaches with patient safety as a top priority (i.e., least likely to
cause harm or side effects even in combination with many other
approaches). In addition to safety, other practical considerations
for choosing favored approaches were suggested as follows:
• Efﬁcacy – greatest potential to achieve the desired action on the
intended target across the widest possible range of cancer types.
• Cost – less expensive is better, and by no means cost prohibitive.
• Intellectual property – free of intellectual property constraints if
at all possible. Approaches that do not have patents, that cannot
be patented, and/or those that have patents that are expired are
to be given priority over those that have existing patents.
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2.1.1. Selection of targets
Extensive discussion took place about the principles of target
selection. Certainly targets that are unique to cancer cells and tumor
microenvironments, and that are not known to cause side effects
when inhibited pharmacologically, would be a primary consideration. Targets induced by viruses or known carcinogens that are
of importance in therapy would also be examined. Consideration
of the nature of mutations in the cancer genome and the role of
epigenetic modiﬁcation were also discussed.
It is understood that great effort has been made to sequence the
cancer genome to identify the most common mutations seen in different cancers. It is also known that different driver mutations may
give rise to variant tumor cells, and the number of driver mutations
required is limited, with just 2–8 per patient, which could potentially be assessed through whole genome sequencing of individual
cancer patients. However, questions arise about treatment, since
most of the currently available drugs are not potent enough to target all susceptible cells. Moreover, the toxicity of existing drugs, if
administered in combination protocols, is severely limiting, even
at the reduced dosages that may be possible when using multiple agents. A strong rationale supports focusing on low toxicity
chemistry (e.g., such as that which has been demonstrated by many
anticancer and chemopreventive phytochemicals as the foundation for a broad-spectrum approach. A number of phytochemicals
enhance absorption of other natural products through such mechanisms as cytochrome P450 modiﬁcation [52], which could also
enhance the possibilities for low-toxicity treatment, i.e., by reducing dosages needed for effective treatment.
Many driver genes are actually tumor suppressor genes, and
in these cases, it is the loss of the tumor suppressor gene that
allows development of cancer. Drugs cannot target these missing genes. Rather they must target unopposed pathways, such
as pathways that are active upstream from the missing suppressor gene. For instance, the tumor suppressor forkhead box 0
(FOX0) normally causes apoptosis. If FOX0 is inactivated in cancer, an unopposed pathway upstream from it is the PI3K/Akt1
signaling pathway, which could alternatively be targeted [53].
The mitogen-activated protein kinase/extracellular-signal regulated kinase/mitogen/extracellular signal-regulated kinase (MEK)
pathway, however, can act as a substitute or compensatory pathway to PI3 K/Akt1. So, in order to effectively shut down replication,
it would seem necessary to address these pathways as well.
Cancer-related signaling pathways, including even those that
become driver pathways, may be epigenetically modiﬁed prior to
their genetic modiﬁcation in cancer pathogenesis [54]. This suggests an emphasis on chemoprevention or treatment of very early
cancers. Targeting may be more straightforward to achieve under
these conditions, since it is easier to modulate wild-type pathways
pharmacologically than to treat the consequences of the onset of
widespread aneuploidy. In this case, the cancer phenotype may
well precede the cancer genotype by years or more. Combining
knowledge of genetic and epigenetic changes in a particular tumor
may result in the targeting of key pathways with fewer agents and
reduced cost.
A more general consideration is that both direct and indirect targets and approaches can be considered. Direct targets are those that
are familiar to us from targeted therapies – oncogenes, tumor suppressor genes, signaling pathways. Indirect approaches, however,
are also potentially useful. For instance, evasion of the immune
system is a hallmark of cancer [27], and immunomodulatory targets and approaches are appropriate to support the capacities
of immune cells to eliminate tumor cells. Immune regulators
are, in a sense, inherently multi-targeted due to the complexity
of the responses they induce [55]. However, immunity is frequently compromised in patients under treatment with cytotoxic
chemotherapies, as well as in the post-surgical period. Immune

system approaches that also support the capacity of patients to
tolerate or recover from surgery or toxic therapies indirectly support the health of cancer patients [56]. The potency of the immune
system is illustrated by ﬁndings that chemotherapy may enhance
antitumor immunity if given in the correct sequence, and that cancer refractory to chemotherapy or immune modulation alone may
become susceptible to both together [57].
2.1.2. Selection of approaches
The need for low-toxicity agents as constituents suggested
that phytochemicals – especially those “pre-screened” in humans
owing to their presence in foods or traditional medicines – should
be carefully considered during approach selection. Each hallmark
team therefore included cancer researchers who had considerable experience working with phytochemicals. In considering
phytochemicals and other low-toxicity agents for inclusion in a
broad-spectrum approach, however, several limitations in the literature promptly become clear.
First, the level of evidence for the effects of natural products on
particular hallmark targets varies widely. The status of laboratory
studies and clinical trials on several well-known phytochemicals, e.g. resveratrol, epigallocatechin gallate (EGCG), curcumin,
lycopene and others, was recently reviewed [58]. The pleiotropic
nature of the effects of these agents on apoptosis and arrest of
cell growth has been emphasized, and their potential use in association with chemotherapy drugs has been acknowledged. Novel
strategies based on a strategic combination of phytochemicals with
broad-spectrum action together with radiation or chemotherapy
agents aimed at overcoming resistance to apoptosis and enhancing
sensitivity to treatment are also currently being considered [59,60].
Second, considerable clinical experience with combinations of
phytochemicals and other natural agents in treatment of cancer
patients exists. Detailed knowledge of the pharmacological effects
of combinations of phytochemicals, however, is limited. There is
a large literature on herbal combinations used in traditional Chinese medicine in both the laboratory and clinic [61–63], but the
quality of older clinical trials is generally low. Additionally, laboratory studies of herbal medicines often use concentrations far
higher than are clinically achievable. Supra-physiological concentrations can produce artifactual or irrelevant mechanisms of action
or cause toxicity. The limited bioavailability of major phytochemicals makes this especially concerning, although products with
improved bioavailability are in development [64]. In general, phytochemical research merits rigorous attention if we hope to gain
a more detailed understanding of how these compounds affect
the cancer hallmarks. Basic research needs to be followed up with
better-designed, statistically powered clinical trials, if we hope to
fully realize the therapeutic potential of phytochemicals.
In addition to laboratory studies and clinical trials, approaches
may be suggested by epidemiological studies and the observations
of integrative medicine, which uses diet and lifestyle therapies
to affect medical conditions including cancer. Observational studies of soy consumption, along with corroborating evidence from
clinical studies, suggest that dietary consumption of soy foods
consistent with levels in the Japanese diet (2–3 servings daily, containing 25–50 mg isoﬂavones) may be associated with reduced risk
of breast cancer incidence and mortality [65]. However, ﬁndings
from animal studies [66] of negative effects of the soy isoﬂavone
genistein on breast cancer and its treatment suggest some caution
and avoidance of simplistic recommendations.
At all levels of investigation, the multi-targeted nature of phytochemicals as well as the integrative therapies is notable. Many
isolated phytochemicals and herbals may alter large numbers of
targets through multifaceted effects on physiology and metabolism
[67–69]. A basic complication of these multi-targeted agents,
however, is the lack of mechanistic understanding and scientiﬁc
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Fig. 2. Hallmarks of cancer, sequenced roughly in the order in which these capabilities are acquired by most cancers, as portrayed in the graphical representation of tumor
evolution.

acceptance of the roles of synergistic or additive molecules in formulation. Although used by human populations for millennia, there
remains a question of how to develop and assess multi-component
natural product formulations that are suitable for large-scale production. Genome-wide screening for assessment of targeted effects
and experimentation with formulation of some herbs typical of traditional Ayurvedic medicine have recently been attempted in Asian
laboratories, and are examples of attempts to better understand
effects of multi-component agents [70–72].
3. Hallmarks of cancer
In this section we provide brief summaries of each hallmark
review included in this special issue of Seminars in Cancer Biology.
Each summary includes the targets and approaches selected in the
hallmark review. Tables summarizing the targets and approaches
and discussion of the cross-validation results follow. In addition, a
summary of the impacts of integrative therapies on cancer-related
molecular targets follows the hallmark summary material.
The hallmark summaries are roughly sequenced to capture the
acquired capabilities of most cancers (see Fig. 2). The section begins
with genomic instability, an enabling characteristic, followed by sustained proliferative signaling and evasion of anti-growth signaling,
two hallmarks that ensure that proliferation is unabated in cancer
cells. These are followed by resistance to apoptosis and replicative
immortality, two layers of defense that are believed to be bypassed
in all cancers. Then we discuss dysregulated metabolism and

tumor-promoting inﬂammation, which signal an important selfreinforcing evolution in the tumor microenvironment. Sections on
angiogenesis and tissue invasion and metastasis speak to disease progression. Finally the tumor microenvironment and immune system
evasion summaries relate to the last lines of defense to be defeated
in most cancers.
3.1. Genomic instability
Genomic instability plays a critical role in cancer initiation and
progression. It provides the means by which a cell or subset of cells
acquire a selective advantage over neighboring cells, enabling outgrowth and dominance in the tissue microenvironment. In normal
cells, the ﬁdelity of the genome is protected at every stage of the cell
cycle by checkpoints. In cancer, the presence of aneuploid cells indicates the failure of one or more of these checkpoints. The resulting
genomic heterogeneity may offer the cancer “tissue” growth advantages under selective pressures, including hypoxia, immune- and
therapy-related challenges. Understanding these checkpoints, and
how they are bypassed in cancer cells, may provide opportunities
for the development of rational combinatorial or broad-spectrum
treatment strategies, including nutraceuticals such as resveratrol
[73,74].
A cell, either transformed or normal, must pass through multiple checkpoints during the process of division. These checkpoints
are operated by functional complexes of proteins that either enable
the cell to pass through the checkpoint (e.g. proto- or oncogenes) or
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prevent the progression through the cell cycle (i.e. tumor suppressors). The abundance of these proteins, and their functionality, can
be modiﬁed by genetic changes to their encoding sequences or by
non-genetic, or epigenetic, changes that regulate their abundance.
Brieﬂy, small changes to the genes that encode proto-oncogenes or
tumor suppressors will positively or negatively impact the function of the gene products. These small changes can be induced by
environmental and lifestyle factors, such as toxic substances, diet,
and smoking, or they can be encoded in the individual at conception. In the case of DNA damage generated by the environment, it
is important that the cell repairs the damage effectively. Dysfunction in the molecules that come together to recognize and respond
to sites of damage is often associated with human cancer. Thus,
an understanding of the genetic or epigenetic status of DNA repair
genes, and of the nutraceuticals that may modulate them [75], provides an opportunity to predict, detect, prevent and treat a variety
of human cancers.
Growing evidences show that vitamins, minerals, and other
dietary factors have profound and protective effects against cancer cells, whether they are grown in the lab, in animals, or
studied in human populations. We have identiﬁed ﬁve targets
against genomic instability: (1) prevention of DNA damage; (2)
enhancement of DNA repair; (3) targeting deﬁcient DNA repair; (4)
impairing centrosome clustering; and, (5) inhibition of telomerase
activity. Vitamins D and B, selenium, carotenoids, PARP inhibitors,
resveratrol, and isothiocyanates are priority approaches against
genomic instability; these approaches may dampen other enabling
characteristics of tumor cells, such as replicative immortality, evasion of anti-growth signaling, tumor promoting inﬂammation, and
oncogenic metabolism [73,76–82].
3.2. Sustained proliferative signaling
Proliferation plays an important role in cancer development
and progression, as manifested by altered expression and activity
of proteins related to the cell cycle [83,84]. Constitutive activation of a large number of signal transduction pathways takes
place in cancer; this also stimulates cell growth. Early in tumor
development a ﬁbrogenic response is often seen. Along with the
development of a hypoxic environment [85,86], this favors the
appearance and proliferation of cancer stem cells (CSCs). The
survival strategies distinguishing CSCs from normal tissue stem
cells involve lack of cellular differentiation and alterations in
cell metabolism, such as higher antioxidant levels [83,84]. These
alterations take place as cells adapt to the changing microenvironment in affected tissue, prior even to the appearance of
tumors. A part of this adaptation embodies epigenetic and genetic
alterations in gene expression [6,87] that also confer resistance
to many cytotoxic treatments [88,89]. Thus, adaptive resistance
is likely acquired early in the pathogenesis of many tumor
types.
Once tumors appear, the continued selection of cells with
sustained proliferative signaling further promotes tumor heterogeneity. This is accomplished by growth and metastasis, which
may be supported by overproduction of appropriate hormones (in
hormonally dependent cancers), by promoting angiogenesis, by
undergoing EMT, by altering the balance between apoptosis, necrosis and autophagy, and by taking cues from surrounding stromal
cells. A number of natural compounds (such as EGCG) have been
found to inhibit one or more pathways that contribute to proliferation [90–92]. Many of these compounds are nontoxic at doses
that inhibit tumor growth and/or prevent the appearance of tumor.
However, one of the keys to their efﬁcacy involves their earliest possible therapeutic application. This is because their efﬁcacy is likely
to be the greatest in target tissues prior to the appearance of a tumor
where cellular heterogeneity is the least. In addition, many of the

steps in carcinogenesis prior to tumor appearance are epigenetic in
nature, and are more easily targeted by existing compounds, most
of which target wild type molecules. This approach limits adaptive resistance, since early intervention does not have to deal with
the issues of aneuploidy, loss of heterozygosity in multiple tumor
suppressor genes, and point mutations in oncogenes. The contribution of bioinformatics analyses will be important for identifying
signaling pathways and molecular targets that may provide early
diagnostic markers and/or critical targets for the development of
new drugs or combinations that block tumor formation. Thus, early
intervention in pathways and molecules that mediate sustained
proliferative signaling will limit adaptive resistance because it targets cells in tissues that have limited genotypic and phenotypic
heterogeneity.
Targets selected for sustained proliferative signaling are
hypoxia-inducible factor-1 (HIF-1) signaling, NF-B signaling,
PI3K/Akt signaling, wingless-type mouse mammary tumor integration site (Wnt) (␤-catenin) signaling, insulin-like growth factor
receptor (IGF-1R) signaling, cell cycle [cyclin-dependent kinases
(CDKs)/cyclins], androgen receptor signaling, and estrogen receptor signaling. Possible therapeutic approaches include curcumin,
genistein and resveratrol.
3.3. Evasion of anti-growth signaling
Normal cells must acquire the ability to continuously proliferate in order to transform into malignant phenotypes. However,
cells have internal programs (anti-growth signaling) to oppose
limitless growth. In order to continue to proliferate, cancer cells
must somehow evade many anti-growth signals. In general, antigrowth signaling is mediated by the activation of tumor suppressor
genes. The Cancer Genome Atlas has compiled data encompassing
all tumor types, which indicates that p53 is the most frequently
mutated tumor suppressor gene followed by PTEN, APC, ATM,
BRCA2, VHL, RB, CDKN2A, BRCA1 and WT1.
Retinoblastoma protein 1 (RB1) was the ﬁrst identiﬁed tumor
suppressor and deletion of this gene is frequently found in cancers
[93]. In many cases, the loss of RB is due to defects in upstream
signaling molecules such as inactivation of INK4. Loss of p16ink4a
results in unopposed activation of CDK4/6, which phosphorylates
the RB protein thereby activating E2F-mediated transcription of
genes involved in entry into the cell cycle [94].
Another tumor suppressor frequently deleted due to chromosomal loss is p53 [95]. In fact, more than 50% of all tumors have
loss of p53 tumor suppressive functions. Recently, mutant p53 has
gained renewed attention due to the fact that along with the loss of
tumor suppressive functions, mutant p53 gains oncogenic/tumor
promoting functions [96].
Epigenetic silencing of tumor suppressor proteins, which
includes DNA methylation, histone methylation and acetylation,
is another mechanism through which tumor cells evade antigrowth signaling. Many tumor suppressor genes have been found
to have promoter hypermethylation in cancers [97]. Finally, antigrowth signaling plays a major role in treatment response and drug
development. For example, the patients with human papilloma
virus-positive oropharyngeal cancer mostly retain wild-type p53
and have better prognosis and survival.
Although genetic alterations are mostly irreversible, epigenetic repressions are potentially reversible and targets for drug
development. At least three histone deacetylase inhibitors, belinostat, vorinostat and romidepsin, are currently approved by the
US FDA for cancer treatment. Many natural compounds also target
the restoration of tumor suppressors through modifying epigenetic changes [98–102]. Thus, approaches to activate anti-growth
signaling will open another chapter for cancer prevention and
therapy.
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The prioritized targets for anti-growth signaling are RB, p53,
phosphatase and tensin homolog (PTEN), Hippo, growth differentiation factor 15 (GDF15), AT-rich interactive domain 1A (ARID1A),
Notch, IGF-1R and others. The approaches are inactivation of E2F
by down regulation of pRb using CDK inhibitors, activation of
p53 through up-regulation of wild-type p53, activation of PTEN
to inhibit PI3K-AKT, activation of Hippo pathways by inhibiting
Yes-associated protein/transcriptional enhancer activator domain
(YAP/TEAD) activity, induction of GDF15 through p53 activation,
activation of ARID1A, blocking Notch pathway, and inhibition of
IGF-1R to restore tumor suppressor pathways. Suggested phytochemicals for these approaches are EGCG, luteolin, curcumin,
genistein, resveratrol, withaferin A, and deguelin. Furthermore,
while the evasion of anti-growth signaling is a critical hallmark
of cancer, other hallmarks are similarly important and a more
integrative approach is necessary to simultaneously target several
hallmarks of cancer to combat this deadly disease.
3.4. Resistance to apoptosis
Apoptosis naturally removes aged and unhealthy cells from
the body [103]. However, in cancer, cells lose their ability to
undergo apoptosis leading to uncontrolled proliferation and multiplication. These malignant cells are often found to overexpress
many of the proteins that play important roles in resisting the
activation of the apoptotic cascade, and one of the major hallmarks of human cancers is the intrinsic or acquired resistance
to apoptosis [104]. Evasion of apoptosis may contribute to tumor
development, progression, and also to treatment resistance, since
most of the currently available anticancer therapies including
chemotherapy, radio- and immunotherapy primarily act by activating death/apoptotic pathways in cancer cells [105]. Hence, a better
understanding of the molecular mechanisms underlying tumor
resistance to apoptotic cell death is expected to provide the basis
for a rational approach to develop molecular targeted therapies.
Apoptosis resistance is multi-factorial and emanates from the
interactions of various molecules and signaling pathways at multiple levels. Several mechanisms exist allowing cells to escape
programmed cell death. Among them is the overexpression of the
anti-apoptotic molecules. B-cell lymphoma-2 (Bcl-2) family proteins play a critical role in the biology of apoptosis resistance.
Robust agents against the Bcl-2 homology domain 3 proteins are
in development and accelerating toward clinical application. Other
cell death mechanisms such as autophagy and necrosis can also
be highlighted and strategies against them exist, including the
use of natural agents such as EGCG. The role of the chaperone
protein heat shock protein 70 (Hsp70) in apoptosis resistance
is important, and natural agents may also address this. Various
molecular mechanisms support resistance to apoptosis in different disease models such as glioblastoma, multiple myeloma and
chronic lymphocytic leukemia. Epigenetic players, particularly the
non-coding RNAs/microRNAs, are also of importance. Novel targets
can be pinpointed, such as ecto-nicotinamide dinucleotide disulﬁde thiol exchanger protein (ENOX) and nuclear export protein
chromosomal regional maintenance protein 1(CRM1), along with
speciﬁc strategies to overcome these important drug resistance
promoters. Other targets include inhibition of Mcl-1, activation
of tumor autophagy, activation of tumor necrosis, inhibition of
Hsp90, inhibition of proteasomes, and inhibition of EGFR and Akt.
Approaches to these targets include gossypol, UMI-77, EGCG, triptolide, PXD, selinexor, and inhibitors of EGFR and Akt. Collectively,
the knowledge gained through greater understanding of the apoptosis resistance targets and speciﬁc strategies is anticipated to
bring forward a broad form of therapy that could result in better treatment outcome in patients suffering from therapy-resistant
cancers.
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3.5. Replicative immortality
Replicative immortality, the ability to undergo continuous selfrenewal, is necessary for propagation of normal germ cells, but is
not a property of normal somatic cells. When acquired by somatic
cells that have sustained genetic damage or instability, replicative immortality allows accumulation of sequential aberrations
that confer autonomous growth, invasiveness, and therapeutic
resistance [106]. As a result, several mechanisms have evolved to
regulate replicative potential as a hedge against malignant progression [107]. Senescence, a viable growth arrest characterized by the
inability of affected cells to resume proliferation in the presence of
appropriate mitogenic factors, is a speciﬁc response to the gradual shortening of chromosomal end structures (telomeres) with
each round of cell replication, and a more general response to oncogenic and genotoxic stresses. Senescence often involves convergent
interdependent activation of tumor suppressors p53 and p16/pRB
[108,109], but can still be induced, albeit with reduced sensitivity, when these suppressors are inactivated. Doses of conventional
genotoxic drugs required to achieve cancer cell senescence are
often much lower than doses required to achieve outright cell
death [110]. Additional targeted therapies may induce senescence
speciﬁcally in cancer cells by blocking cyclin-dependent kinase
mediated inhibition of RB-family proteins [111], or by exploiting
cancer cells’ heightened requirements for maintenance of telomere
length through the action of the enzyme telomerase [112]. Developing optimized and truly holistic cancer prevention and treatment
regimens will likely incorporate strategies that target replicative
immortality.
The chief advantage to be gained by the use of senescenceinducing therapeutic regimens is elimination of the tumor’s
repopulating ability with reduced collateral damage compared to
conventional cytotoxic regimens. There are, however, certain questions and risks associated with this strategy that must be addressed
before its clinical adoption. In the case of telomere and telomerase
based strategies, replicative senescence may occur more readily
in rapidly dividing cancer cells bearing short telomeres than in
slowly dividing stem cells with comparatively longer telomeres,
but telomere lengths in cancer cells may still be long enough to permit sufﬁcient population doublings for invasion and metastases to
occur [112] Moreover, telomere dysfunction promotes the development of chromosomal instability, which in turn can generate
mutations that enable cells to become drug resistant and/or activate mechanisms based on alternative lengthening of telomeres
for telomere maintenance and/or become more malignant [113].
High priority should therefore be given to further research into the
determinants of senescence stability, as the implications of delayed
cell cycle re-entry, permanent cytostasis, or eventual clearance may
be profoundly different. Lower doses of genotoxic drugs needed to
induce senescence may reduce collateral damage to critical normal cells, but allow establishment of dormancy and/or adaptive
resistance by cancer cells. The microenvironmental and systemic
effects of senescent cells also need further clariﬁcation, as factors
secreted by senescent cells may promote tumorigenic changes in
nearby cells. Conversely, since it is almost impossible to kill all
the cells in malignant tumors even using the highest tolerated
doses of chemotherapy, combined use of an agent that induces or
enhances stable senescence in the cancer cells that manage to retain
viability might additively or synergistically increase therapeutic
efﬁcacy.
A number of potential targets can be singled out for further research, including telomerase, human telomerase reverse
transcriptase (hTERT), mammalian target of rapamycin (mTOR),
CDK4/6, CDK 1/2/5/9, Akt and PI3K. Several approaches deserve
further research, although the activity of the phytochemicals in
particular is still far from clinical utility. These include imetelstat,
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genistein, perillyl alcohol, palbociclib, dinaciclib, curcumin and
EGCG.
3.6. Dysregulated metabolism
Dysregulated metabolism is a hallmark of cancer in which many
cancer cells show increased glucose uptake and produce lactate.
This characteristic is often called the “Warburg effect” [114], but
how and why cancer cells reprogram their metabolic state is not
well understood. Recent research has focused on understanding the
metabolic changes accompanying oncogenesis [27]. A new model
of cancer metabolism positions metabolic rewiring in cancer as
a coordinated process to support rapid cellular proliferation by
tuning cellular energy production needs toward biosynthetic processes. Indeed, several metabolic shifts associated with cancer can
be linked to cellular growth, which serve to support biosynthesis
of lipids, proteins, nucleic acids required for tumor formation and
survival [115].
In several cases, expression of oncogenes and/or loss of tumor
suppressors lead directly to changes in metabolism, by expression,
activity, or ﬂux of key metabolic nodes. Several components of
glucose and glutamine metabolism have emerged as important regulators of metabolism in cancer. In glucose metabolism, hexokinase
2 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
(PFKFB3) and pyruvate kinase isoform M2 (PKM2) all regulate glycolytic ﬂux. Using a “kitchen sink” analogy for glycolysis, both HK2
and PFKFB3 are regulators of the faucet, and ﬁll up the sink. Conversely, PKM2 regulates the drain. Cancer metabolism turns on the
faucet and plugs the drain, which over-spills the glycolytic pathway and provides metabolites used as building blocks for cellular
growth. Efforts are underway to identify therapeutic strategies to
“turn off the faucet” or “unplug the drain” in glycolysis, limiting cellular growth in cancer. Recent studies have also determined that
glutamine is used as a fuel (glutaminolysis) in proliferating cancer cells. Glutamine oxidation can provide carbon and nitrogen for
growth, and therefore is an attractive therapeutic target in cancer. Additionally, mutations in genes encoding enzymes directly
involved in metabolic pathways have been associated with several types of cancer. Rather than acting as a bystander or facilitator
of oncogenesis, aberrant metabolism now has a pro-oncogenic role
and has led to the redeﬁnition of some metabolites as ‘oncometabolites’ [116]. Indeed, these oncometabolites are powerful inﬂuencers
of proliferation, and are also positioned as new therapeutic targets.
In principle, a broad-spectrum approach to target metabolic
shifts in cancer is likely to be a promising therapeutic strategy.
However, studies using this approach to target dysregulated
metabolism in cancer are in their infancy. Lessons could be
learned from other strategies to target mitochondria or to target
metabolism in order to identify efﬁcacious and safe therapies
targeted at cancer metabolism; some drugs targeting metabolism
are being re-purposed for their antitumorigenic effects. Several approaches could be mentioned, such as 3-bromopyruvate,
1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK-15), 6-[(3aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulﬁnyl)5H-thieno[2 ,3 :4,5]pyrrolo[2,3-d]pyridazin-5-one
(TEPP-46),
dichloroacetate, hexachlorophene, bis-2-(5-phenylacet-amido1,2,3-thiadiazol-2-yl)ethyl sulﬁde (BPTES) and 2,3-Dihydroxy6-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar-boxylic
acid (FX11), but data for these must be regarded as extremely
preliminary, and they lack sufﬁcient justiﬁcation to be included in
therapy without further study. Most target proteins or pathways
identiﬁed as having potential to manipulate cancer metabolism
have not been directly tested in the context of other hallmarks. The
emerging efﬁcacy of physiological interventions that manipulate
cancer outcomes, such as fasting, calorie restriction, or exercise,
could inﬂuence cancer metabolism and other hallmarks of cancer

[117]. Future studies directly testing the ability to manipulate
dysregulated metabolism in cancer will be an important and
exciting new area of cancer biology that has potential for treating
a variety of cancers.
3.7. Tumor-promoting inﬂammation
Virchow ﬁrst proposed the role of inﬂammation in cancer in
1863, while observing the presence of leukocytes in neoplasms,
and empirical evidence has since underscored the importance
of this linkage [118,119]. The inﬂammatory milieu promotes a
cellular microenvironment that favors the expansion of genomic
aberrations and the initiation of carcinogenesis [120]. Chronic
inﬂammation is linked to various phases of tumorigenesis, such as
cellular proliferation, transformation, apoptosis evasion, survival,
invasion, angiogenesis and metastasis [121–123]. Inﬂammation is
also known to contribute to carcinogenesis through the generation of reactive oxygen species (ROS) and reactive nitrogen species
which can damage DNA at the site of the tumor [124]. Free radicals and aldehydes, produced during chronic inﬂammation, can also
induce deleterious gene mutation and post-translational modiﬁcations of key cancer-related proteins [125].
In addition, chronic inﬂammation has an inﬂuence on immune
system constituents that are directly linked with cancer progression. Under normal conditions, immune cells, including
macrophages, granulocytes, mast cells, dendritic cells, innate lymphocytes, and natural killer (NK) cells serve as the front line
of defense against pathogens. When tissue disruption occurs,
macrophages and mast cells secrete matrix-remodeling proteins,
cytokines and chemokines, which activate local stromal cells (e.g.,
ﬁbroblasts, adipocytes, vascular cells) to recruit circulating leukocytes into damaged tissue (acute inﬂammation), to eliminate
pathogens [126]. However, when these processes are initiated in
the tumor microenvironment, they are not resolved, which leads to
chronic inﬂammation of the “damaged” (tumor) tissue. Thus, while
acute inﬂammation normally supports and balances two opposing
needs for the repair of damaged tissues (apoptosis and wound healing), chronic inﬂammation represents a loss of this balance and the
resulting conﬂuence of factors has deleterious implications for the
immune system [127].
Accordingly, the relationship between tumor-promoting
inﬂammation and cancer is important to consider. Macrophage
migration inhibitory factor, cyclooxygenase-2 (COX-2), NF-B,
tumor necrosis factor alpha (TNF-␣), inducible nitric oxide synthase (iNOS), Akt, and chemokines are important antiinﬂammatory
targets that might be suitable for a multi-pronged therapeutic
approach to inﬂammation suppression. Additionally, curcumin,
resveratrol, EGCG, genistein, lycopene, and anthocyanins are
forms of low-cost chemistry with little to no toxicity that could be
employed to reach these targets.
Future translational work should make use of promising agents
such as these (combined as constituents within a multi-pronged
antiinﬂammatory approach) bearing in mind that some of these
targets impact the immune system and can increase the risks associated with infection. Bioavailability challenges are also a concern
for a number of these agents but recent advances in delivery systems will help address this issue.
3.8. Angiogenesis
Angiogenesis, the expansion of an existing vasculature, is the
main mechanism of blood vessel growth, and is therefore essential
for tumor development [128]. Tumor angiogenesis is switched on
by changing the balance between angiogenic factors and inhibitors
in favor of angiogenesis [129], a process induced by tumor hypoxia
as the tumor grows beyond a size of approximately a few mm3
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[128,130]. At more advanced stages, progressive genomic instability in the tumor leads to mutations in pathways regulating
the production of multiple angiogenic factors [131], and stroma
cells also become important sources of sustained angiogenic factor
production [29]. These collectively result in a stronger and more
complex angiogenic factor proﬁle. It is therefore not surprising
that targeted neutralization of a single angiogenic factor, which
has been the focus for antiangiogenic cancer therapy so far, rarely
produces long-term antitumor effects [29].
Due to the multifactorial nature of tumor angiogenesis this process is likely to be more efﬁciently treated by targeting multiple
aspects of tumor angiogenesis and vascular dysfunction at the
same time. Ten of the most important targets for tumor angiogenesis and vascular dysfunction are to inhibit endothelial cell
migration/tip cell formation, reduce structural abnormalities of
tumor vessels, reduce hypoxia, inhibit lymphangiogenesis, reduce
elevated interstitial ﬂuid pressure, reverse poor perfusion, normalize disrupted circadian rhythms, suppress tumor-promoting
inﬂammation, deactivate tumor-promoting ﬁbroblasts and normalize tumor cell metabolism/acidosis.
Currently available non-speciﬁc antiangiogenic agents, able to
perform some of these tasks, are however quite toxic, which renders them unsuitable for long-term use [131–133]. There is an
urgent need to identify alternative compounds that could be used
in combination over extended periods of time, targeting tumor
angiogenesis broadly and thus lowering the risk of resistance. Plantderived compounds, phytochemicals, are in many cases better
tolerated than the synthetic analogs used in cancer therapy today.
Furthermore, they often exhibit broader mechanisms of action and
sometimes even higher afﬁnity against important cancer targets
compared to the synthetic alternatives [134]. Ten phytochemicals
that may be effective as approaches to neutralize the 10 identiﬁed targets are oleanoic acid, tripterine, silibinin, curcumin, EGCG,
kaempferol, melatonin, enterolactone, withaferin A and resveratrol. Further study is needed to determine the optimal use and
combination of these phytochemicals in antiangiogenic therapy,
focusing on delivery, toxicity and their use in prophylactic regimens.
3.9. Tissue invasion and metastasis
Cancer causes substantial patient morbidity and mortality globally, making it a key health issue. Metastatic dissemination of the
disease to distant sites impacts prognosis, with metastatic diseases accounting for a vast percentage of cancer patient mortality
[27,135,136]. Cancer cells must overcome particular obstacles in
order to successfully disseminate to and establish at a secondary
location, progressing through the metastatic cascade. Successful
progression through this cascade is linked with numerous established changes in cellular functions leading to the acquisition
of an invasive phenotype. This involves loss of cell-cell contact
with the main tumor body, invasion, degradation and migration
through surrounding tissue and extracellular matrix, secretion
of angiogenic/lymphangiogenic factors and intravasation to the
blood/lymph vessel, transport around the body and evasion of the
immune system, extravasation at the secondary site and establishment of a secondary tumor [137,138].
Hence, factors inﬂuencing these processes such as cell adhesion molecules, proteolytic matrix degrading enzymes, cell motility
and factors involved in the process of EMT have all been subject to
scientiﬁc scrutiny. Additionally, the complex heterogeneity within
tumors, together with cellular interactions between tumor cells
and other, non-cancerous, cell types have been established to play
key roles in metastatic dissemination and add further complexity to this cascade [136,137]. While advances in the ﬁeld of cancer
research have been made, the process of cancer metastasis and the
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factors governing cancer spread and establishment at secondary
locations are still poorly understood. Current treatment regimes
for metastatic disease pose many adverse effects, which can further
negatively impact on a subset of patients generally presenting with
poorer health conditions. Hence there is a great need to develop
new therapeutics that not only target tumor growth and inhibit
metastasis but that also have a lower toxicity and reduced inherent
side effects. Factors associated with metastasis such disruption of
E-cadherin and tight junctions, key signaling pathways, including
urokinase-type plasminogen activator, PI3K/AKT, focal adhesion
kinase, ␤-catenin/zinc ﬁnger E-box-binding homeobox 1 and transforming growth factor (TGF)-␤, together with inactivation of activator protein 1 (AP-1) and suppression of matrix metalloproteinase9 (MMP-9) activity should be considered as key research
priorities.
The need can also be highlighted for new, low toxicity
compounds, which interfere with these processes but remain
inexpensive alternatives that are readily available and free from
intellectual property. Phytochemicals, or natural products, such as
those from Agaricus blazei, Albatrellus conﬂuens, Cordyceps militaris,
Ganoderma lucidum, Poria cocos and Silybum marianum, together
with diet-derived fatty acids gamma-linolenic acid and eicosapentaenoic acid and inhibitory compounds have potential to inhibit
these key metastatic events. These potential targets and strategies
thus present new therapeutic opportunities to both manage cancer metastasis as well as having holistic effects against many of the
hallmarks of cancer.
3.10. Tissue interactions in the tumor microenvironment
Cancer arises in an in vivo tumor microenvironment. This
microenvironment is a cause and consequence of tumorigenesis,
and consists of cancer cells and host cells that co-evolve dynamically through indirect and direct cellular interactions, producing
metabolites and secreting factors that affect cancer progression
[139,140]. In turn, this environment regulates the ability of a cancer to grow and survive via multiscale effects on many biological
programs including cellular proliferation, growth and metabolism,
as well as angiogenesis and hypoxia, innate and adaptive immunity [141]. Speciﬁc biological programs could be, based on our
most recent understanding, exploited as targets for the prevention
and therapy of cancer, including: the inhibition of cholesterol synthesis and metabolites, ROS and hypoxia, macrophage activation
and conversion, regulation of dendritic cells, regulation of angiogenesis, ﬁbrosis inhibition, endoglin, and cytokine signaling. These
programs emerge as examples of important potential nexuses in
the regulation of tumorigenesis and the tumor microenvironment
that can be targeted.
Potential targets include metabolic programs that may broadly
inﬂuence many cell biology programs that impact tumorigenesis and the tumor microenvironment (cholesterol synthesis
and metabolites, ROS and hypoxia), inﬂammation, innate and
adaptive immunity-related programs (macrophage conversion,
dendritic cell activation, immune signaling), host microenvironment associated cellular programs (ﬁbrosis, angiogenesis), and
cytokine-mediated regulatory programs (IL-6, endoglin, and JAK).
We have particularly focused on identifying approaches for inhibiting these targets that included natural products that have been
suggested to have signiﬁcant anticancer activity. Some of these
molecules may more generally inﬂuence tumorigenesis and the
microenvironment (berberine), others more speciﬁcally target
ROS (resveratrol, desoxyrhapontigenin), macrophage conversion
(onionin A), indoleamine 2,3-dioxygenase (IDO) regulation of
dendritic cells (EGCG), cholesterol synthesis (genistein), ﬁbrosis
(naringenin), inﬂammation and immune signaling (piperine) and
JAK signaling (zerumbone). This approach will provide a starting
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point for examining synergies that might be anticipated in testing
certain targets and/or mixtures of natural chemical constituents
that may modulate the tumor microenvironment in the treatment
and prevention of cancer.

3.11. Immune system evasion
Tumors evade immune attack by several mechanisms including generation of regulatory cells and their secretions, defective
antigen presentation, induction of immune suppressive mediators
either by cancerous cells themselves or by those in the microenvironment, tolerance, immune deviation and apoptosis.
Current approaches to immune therapy include (a) cellular targets, (b) molecular targets, (c) vaccination therapy, (d) therapy by
phytochemicals, (e) adoptive T cell therapy and (f) immunomodulatory antibodies. Of these anticancer agents, the most important
are those that are targeted in nature and to lesser extent, those
that are non-speciﬁc in nature. Targeting speciﬁc costimulatory
molecules such as cytotoxic T-lymphocyte-associated protein-4
(CTLA-4) [142] or programmed cell death protein (PD1/PD-L1)
[143] is considered an important anticancer strategy. Also, antiPD-1 antibodies are showing enormous therapeutic potential in
advanced cancers. Targets that are considered appropriate for
broad-spectrum, low-toxicity therapeutics are less speciﬁc and
include enhancing Th1 responses, enhancing ␥␦ T cells, activation
of macrophages, inhibition of Treg lymphocytes, enhancing natural
killer cell activity and induction of IL-12.
There are a number of important nonspeciﬁc anticancer agents
that have been reported, including vaccination therapy, as well
as nonspeciﬁc bacteria-based therapies [144], and phytochemicals
[145–147]. Phytochemicals (the biologically active components of
fruits and vegetables) have been shown to exert protective effects
against cancer. Examples of potential phytochemical approaches
include extracts of Ganoderma lucidum, Trametes versicolor, Astragalus membranaceus, and Lentinus edodes, as well as astaxanthin
and the polyphenol resveratrol analog HS-1793. There is, however,
a downside to phytochemical therapy such as their poor absorption by humans and rapid metabolism and excretion. More work is
required to assess which phytochemicals block evasion of immune
surveillance and also to determine which phytochemicals promote
antitumor responses in cancer patients before these can be recognized for therapeutic value in the clinic.

4. Summary of ﬁndings on targets and approaches in
hallmark reviews
As described above, a cross-validation process was employed
to review the proposed actions on each target and all of the
approaches for known effects on other hallmark areas and
the tumor microenvironment. Anticarcinogenic synergies and
confounding/procarcinogenic effects were then compiled and
summarized in Tables 1–3. Supplemental Table S1, a sample crossvalidation table for dysregulated metabolism approaches, was used
in construction of Tables 2 and 3. Supplemental Tables S2 and S3
contain the aggregated cross-validation tables from each review
(with references omitted). More detailed discussion of these interactions can be found in the individual hallmark reviews.
Table 1 shows an alphabetical listing of prioritized targets from
each hallmark review, as well as the number of contrary, controversial, none known and complementary interactions with all
other hallmarks. Dysregulated metabolism targets do not appear
in the table; too little is known about the targets in this new area
of research to reliably assess their interactions with other hallmarks. Of these relationships, 3.98% were contrary, 7.62% were

controversial, 21.74% of interaction assessments found no known
relationship, and 66.71% were complementary.
Table 2 shows the prioritized therapeutic approaches–the phytochemicals, plant extracts and drugs chosen as modiﬁers of the
priority targets. Of these, 1.08% were contrary, 7.62% were controversial, 34.05% had no known relationships and 62.1% were
complementary. Both contrary and controversial interactions indicate potential conﬂict among the targets and approaches selected
for different hallmarks that could result in a broad-spectrum
approach with antagonistic, rather than synergistic effects.
The small number of contrary and controversial interactions is
encouraging, and suggests that the potential for negative interactions among the selected targets and approach may be limited.
However, this may also reﬂect the common bias in the literature to
publish positive antitumor effects. Nearly a third of potential interactions were listed as having no known relationship, suggesting the
need for substantially more research in this area. The large number
of complementary interactions is also encouraging but may result
from indirect or bystander effects.
Table 3, in which the different types of interactions of both
targets and approaches are listed for each hallmark, reﬂects different levels of knowledge regarding hallmarks, as well as varying
prevalence of complementary approaches. Genomic instability has
the largest number of unknown relationships with the targets and
approaches. On the other hand, tumor microenvironment, tissue
invasion and metastasis and resistance to apoptosis have the highest number of complementary interactions for both targets and
approaches. Small numbers of contrary interactions were found
for the different hallmarks for both targets and approaches, but
the number of targets for replicative immortality and angiogenesis, reﬂecting mixed positive and negative interactions, were larger
than for other hallmarks.
There are a number of limitations that should be noted in this
delineation of cross-hallmark relationships. First, the researchers
who assembled these results were not asked to distinguish between
direct effects on other hallmark areas and reported effects on other
hallmark areas that may have resulted in an indirect or “bystander”
effect mediated through a different mechanism. In many cases, but
not all, this distinction was made. Therefore it is likely that some of
the complementary interactions do not represent a fully independent cross-hallmark relationship, but rather are simply indicative
of some sort of downstream effect (e.g., within a signaling cascade or via some other signaling molecule that exerts pleiotropic
effects). However, we did not feel that this project needed to investigate the nature of these complementary interactions in detail,
especially since the clinical impacts of these interactions would be
similar for indirect and direct effects. Instead, our main concern was
focused on the possibility that a large number of cross-hallmark
relationships might be revealed where actions with procarcinogenic or tumor-promoting potential had been reported. It was more
important to identify contrary and controversial cross-hallmark
interactions than complementary ones, since targets or approaches
that exert procarcinogenic actions would normally need to be more
carefully assessed (or avoided altogether) in the development of
combination approaches or interventions.
The second limitation of these reports of cross-hallmark relationships is related to data quality. In some instances, the available
evidence used to support the indication of a cross-hallmark relationships was robust, consisting of multiple studies involving
detailed in vitro and in vivo ﬁndings. In other instances, however,
the underlying evidence that was used to report the existence of
a cross-hallmark relationship was quite weak (e.g., consisting of
only a single in vitro study involving a single cell-type). Again, the
overarching goal in this project was to create a foundation that
would allow us to look systematically across the literature in each
of these areas, to help us shape the selection of the targets and
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Table 1
Prioritized targets with summary of information from cross-validation tables.
Hallmarka,b

Target (action on target)

Contrary

Controversial

Complementary

None known

AP, RI, TPI
SPS
TIM
EAG
AP
RI
RI
SPS
GI
TME
TME
TPI
TPI
AN
GI
GI
EAG, TIM
EAG
AP
AN
TME
AN
AP
SPS
EAG
TIM
TME
EAG
SPS
AP
RI
AN
TME
EAG, SPS
IE
TME
TPI
TME
AN
TME
IE
AP
TPI
TIM
RI
SPS, TIM, TPI
IE
EAG
AP
RI
EAG, SPS, TIM
AN
AP
TME
AN
GI
GI, RI
TIM
IE
TIM
TPI
IE
AP
AN
AP
AN
AN
TIM
TME
EAG
SPS
EAG
TIM
IE
Totals:
Percentages:

Akt (inhibit)
Androgen receptor signaling (suppress)
AP-1 (inhibit)
ARID1A (activate)
Bcl-2 (inhibit)
CDK 1/2/5/9 (inhibit)
CDK 4/6 (inhibit)
Cell cycle (CDKs/cyclins) (attenuate)
Centrosome clustering (block)
Cholesterol metabolites (inhibit)
Cholesterol synthesis (inhibit)
COX-2 (inhibit)
CXC chemokine (inhibit)
Disturbed circadian rhythms (normalize)
DNA damage (prevent)
DNA repair (enhance)
E-cadherin (restore)
E2F (inactivate)
EGFR (inhibit)
Elevated interstitial ﬂuid pressure (reduce)
Endoglin (inhibit)
Endothelial cell migration/tip cell formation (inhibit)
ENOX (inhibit)
Estrogen receptor signaling (suppress)
Endoplasmic reticulum stress (induce)
FAK signaling (inhibit)
Fibrosis (inhibit)
Growth differentiation factor 15 (induce)
HIF-1 signaling (inhibit)
Hsp90 (inhibit)
hTERT (inhibit)
Hypoxia (reduce)
IDO (inhibit)
IGF-1R (inhibit)
IL-12 (induce)
IL-6 (inhibit)
iNOS (block)
JAK (inhibit)
Lymphangiogenesis (impede)
M2 macrophage conversion (inhibit)
Macrophages (activate)
Mcl-1 (inhibit)
MIF (block)
MMP-9 (suppress)
mTOR (inhibit)
NF-B signaling (inhibit)
NK cell activity (promote)
NOTCH (block)
Nuclear exporter CRM1 (inhibit)
PI3K (inhibit)
PI3K/Akt signaling (inhibit)
Poor perfusion (improve)
Proteasome (inhibit)
ROS (inhibit)
Structural abnormalities of vessel walls (inhibit)
Target deﬁcient DNA repair
Telomerase (inhibit)
TGF-␤ (inhibit)
Th1 response (promote)
Tight junctions (promote)
TNF-␣ (block)
Treg lymphocytes (inhibit)
Tumor autophagy (activate)
Tumor cell metabolism/acidosis (normalize)
Tumor necrosis (activate)
Tumor-promoting ﬁbroblasts (deactivate)
Tumor-promoting inﬂammation (suppress)
Urokinase plasminogen activator (suppress)
VEGF (inhibit)
Wildtype p53 (upregulate)
Wnt (B-catenin) (inhibit)
YAP/TEAD activity (inhibit)
␤-catenin/ZEB1 (inactivate)
␥␦ T-cell activity (promote)

0
0
1 RI
1 TIM
0
1 TME
1 GI
2 IS, TIM
0
0
0
1 AN
0
0
1 TPI
1 TPI
1 AN
1 TME
0
0
0
0
0
1 TIM
2 AN, TIM
0
0
1 GI
0
1 TIM
0
0
0
0
1 AP
0
1 AN
0
0
0
2 SPS, TIM
0
0
0
0
0
0
1 AN
0
0
0
0
0
0
0
1 TPI
0
1 RI
1 TPI
1 AN
1 IE
0
1 TPI
0
2 AN, TME
0
0
1 RI
0
0
0
0
0
2 TPI, AN
32
3.93%

0
2
0
0
1
0
1
0
0
0
1
0
3
2
3
3
4
0
0
0
1
0
0
3
1
0
0
0
0
0
1
1
1
0
0
3
1
0
1
0
2
0
0
1
2
2
0
0
0
0
0
1
0
2
0
2
0
2
0
0
1
1
4
0
3
0
0
0
3
0
3
0
0
0
62
7.62%

11
8
7
5
9
9
8
9
8
7
8
10
5
9
5
5
4
7
10
9
5
7
5
7
7
9
6
5
9
8
8
10
7
9
5
7
6
10
4
7
3
10
9
7
8
8
7
8
6
11
11
7
10
7
7
5
10
7
5
6
8
6
4
9
5
9
7
7
8
10
7
6
7
4
543
66.71%

0
1
3
5
1
1
1
0
3
4
2
0
3
0
2
2
2
3
1
2
5
4
6
0
1
2
5
5
2
2
2
0
3
2
5
1
3
1
6
4
4
1
2
3
1
1
4
2
5
0
0
3
1
2
4
3
1
1
5
4
1
4
2
2
1
2
4
3
0
1
1
5
4
5
177
21.74%

a
For each target, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary relationships, contrary
relationships, no known relationships and controversial relationships. For targets that have contrary relationships, the conﬂicted hallmark(s) are shown. Totals and percentages of each
type of relationship are shown at the end of the table.
b
AN, angiogenesis; AP, resistance to apoptosis; DM, dysregulated metabolism; EAG, evasion of anti-growth signaling; GI, genomic instability; IE, immune evasion; RI, replicative
immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TME, tumor microenvironment; TPI, tumor promoting inﬂammation.
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Table 2
Prioritized approaches with summary of information from cross-validation tables.
Hallmarksa,b

Approaches

Contrary, conﬂicted hallmarks

Controversial

Complementary

None known

DM
TIM
TPI
IE
IE
TME
DM
GI
TIM
AN, EAG, RI, SPS, TME, TPI
EAG
TME
DM
RI
AN, AP, EAG, RI, TME, TPI
TIM
AN
DM
TIM
TIM
IE
EAG, RI, SPS, TME, TPI
AP
TIM
DM
DM
IE
RI
GI
AN
IE
EAG
TPI
AN
DM
TME
AN
TME
TIM
RI
GI
RI
TME
DM
TIM
AN, DM, EAG, GI, SPS, TME, TPI
GI
AP
AN, TIM
DM
IE
AN
AP
AP
GI
GI
AN, EAG
TME
TIM
Totals:
Percentages:

3-bromopyruvatec
5,6-dihydro-4H-pyrrolo[1,2-b]-pyrrazolesc
Anthocyanins
Astaxanthin
Astragalus membranaceus polysaccharide
Berberine
BPTESc
Carotenoids
Cordycepin
Curcumin
Deguelin
Desoxyrhapontigenin
Dichloroacetatec
Dinacicilibc
EGCG
Eicosapentaenoic acid
Enterolactone
FX11c
Gamma linolenic acid
Ganoderic acids
Ganoderma lucidum polysaccharide
Genistein
Gossypol
Grifolin
GW5074c
Hexachlorophenec
HS-1793 (polyphenol resveratrol analog)c
Imetelstatc
Isothiocyanate
Kaempferol
Lentinus edodes polysaccharide
Luteolin
Lycopene
Melatonin
Metforminc
Naringenin
Oleanoic acid
Onionin A
Pachymic acid
Palbociclib c
PARP inhibitorc
Perillyl alcohol
Piperine
PK15c
Polysaccharide (G. lucidum)
Resveratrol
Selenium
Selinexorc
Silibinin
TEPP-46c
Trametes versicolor polysaccharide-k
Tripterine
Triptolide
UMI-77c
Vitamin B
Vitamin D
Withaferin A
Zerumbone
␤-(1-6)-D-glucan (A. blazei)

0
0
0
0
1 AN
1 IE
0
0
0
0
0
0
0
0
0
0
0
1 GI
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1 TIM
0
0
1 IE
0
0
0
1 TPI
0
0
0
0
0
1 IE
0
0
0
0
0
0
7
1.08%

0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
5
0
0
1
0
0
1
0
0
0
0
0
0
1
2
0
0
0
0
0
0
0
0
1
2
2
0
0
0
0
0
0
0
2
0
0
0
0
18
2.77%

7
2
9
7
6
9
5
10
8
11
7
2
7
6
11
8
7
2
7
7
9
6
9
6
3
6
5
4
10
7
8
9
8
10
10
6
10
1
6
4
9
10
7
6
8
9
6
3
11
3
3
5
9
5
3
10
9
6
6
403
62.10%

4
9
2
4
4
1
6
0
3
0
4
9
4
5
0
3
4
8
4
4
2
0
2
5
7
5
6
6
1
4
3
2
3
1
0
3
1
10
5
6
2
1
3
5
2
0
2
8
0
8
8
6
1
6
6
1
2
5
5
221
34.05%

a
For each approach, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary
relationships, contrary relationships, no known relationships and controversial relationships. For approaches that have contrary relationships, the conﬂicted hallmark(s) are
shown. Totals and percentages of each type of relationship are shown at the end of the table.
b
AN, angiogenesis; AP, resistance to apoptosis; DM, dysregulated metabolism; EAG, evasion of anti-growth signaling; GI, genomic instability; IE, immune evasion; RI,
replicative immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TME, tumor microenvironment; TPI, tumor promoting inﬂammation.
c
Targeted therapy, synthetic compound or natural product analog/derivative.

approaches in order to comprehensively counter tumor growth
pathways. So although we realized that not all of these reports
of cross-hallmark relationships represented the same level of evidence, we still wanted to examine available evidence to ﬂag targets
and approaches where procarcinogenic actions had been reported.

There was also considerable debate within the task force over
the value of tables containing only a simpliﬁed indication of a
relationship (i.e., + or −) supported by evidence that varied considerably in quality. But since many individual studies and reviews
that focus on therapeutic approaches fail to work systematically

64
0
9
0
60
1
11
0
22
3
39
12
42
0
27
6

40
2
23
7

61
3
9
7
65
5
7
3
44
2
34
4
55
0
23
5

44
9
15
12

Tumor
Microenvironment
Tissue invasion
and metastasis
Angiogenesis
Immune
system
evasion
Dysregulated
metabolism

across the spectrum of incidental actions that might result from
combining therapies, it was our opinion that a tabularized framework was the only way to ensure that we had assembled a complete
view of cross-hallmark activity.
The types of approaches selected differed among different
review teams. While some review teams selected all or mostly phytochemicals or plant extracts, some teams felt that the evidence for
these was insufﬁcient, and emphasized other types of molecules,
including drugs in development. These may pose more difﬁculties
for translational investigators due to intellectual property, toxicity or other concerns, but may offer advantages in a more clear
understanding of their mechanisms. We suggest, however, that the
approaches as well as the targets presented in Tables 1 and 2 can
be viewed as simply a model for broad-spectrum cancer therapies,
rather than as a ﬁnal list. Some of the recommended approaches
are clearly experimental, and further research will likely discover
compounds, phytochemical or synthetic, that are not on this list
that may be useful in a broad-spectrum approach. The prevalence
of interactions where no interactions were found – over 20% for
targets and over 30% for approaches – also suggests caution and
a need for further research investigating potential cross-hallmark
relationships as well as other mechanisms that may lead to toxicities.
Bioavailability of the phytochemicals chosen will also be a
concern for future studies. The need for development of better
preclinical models for screening compounds and testing rationally
designed combinatorial therapies composed of compounds from
any source is also obvious, and should clearly be a ﬁrst step in the
development of the broad-spectrum approach.

37
0
37
1
62
0
11
1
50
0
17
5
51
0
20
8
Therapeutic approaches
35
Complementary
0
Contrary
39
None known
1
Controversial

44
1
26
5

34
0
37
12
62
1
13
4
53
0
20
7
52
1
24
5
30
2
52
1
Targets
Complementary
Contrary
None known
Controversial

53
6
18
6

Replicative
immortality
Resistance
to
apoptosis
Evasion of
anti-growth
signaling
Tumor-promoting
inﬂammation
Genomic
instability

Sustained
proliferative
signaling
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4.1. Role of integrative therapies in the broad-spectrum approach

Type of
relationship

Table 3
Numbers of targets and therapeutic approaches for each hallmark with the following relationships: complementary relationship, contrary relationship, no known relationship and controversial relationship. Based on crossvalidation tables.
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Integrative medicine is an approach to health and healing
that “makes use of all appropriate therapeutic and lifestyle
approaches, healthcare professionals and disciplines to achieve
optimal health and healing” [148]. A comprehensive integrative medicine intervention for cancer patients typically includes
nutrition education, mind-body medicine and physical activity
components, as well as dietary supplements including herbs,
nutraceuticals and phytochemicals [3,149]. Such an intervention may contribute uniquely to a broad-spectrum therapeutic
approach through its impact on a wide variety of relevant molecular
targets and hallmarks. Hallmarks that may be particularly impacted
include genomic instability, tumor-promoting inﬂammation, dysregulated metabolism and immune system evasion. Because of
their susceptibility to manipulation by diet, exercise and supplementation, these may be characterized as metabolic hallmarks.
Nutrition has long been the primary focus of research on integrative interventions for cancer. The World Cancer Research Fund
and the American Institute for Cancer Research ﬁnd that diets high
in fruits and vegetables substantially reduce risks of several cancers
[150]. Cancer prevention diets are also suitable after a cancer diagnosis [151]. For example, colon cancer patients eating a Western
diet after diagnosis were at higher risk for recurrence and mortality
than those with healthy diets [152]. Breast cancer patients who followed low-fat diets were found to have lost weight and had lower
recurrence risks, especially among patients with estrogen receptornegative cancers [153]. Trials of diets enriched in whole grains,
low-glycemic diets, and both low-fat diets and Mediterranean diets
enriched in olive oil and almonds reduced levels of inﬂammation as measured by CRP [154–157]. Low fat diets, weight loss
and supplements (anthocyanins and ﬁsh oil) have been observed
in randomized trials to reduce cytokines and signaling molecules
[158–161]. Mind-body interventions have emphasized immune
targets, with ﬁndings of interventional trials including activation of
T cells and lymphokine-activated killer cells and increased natural
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killer cell activity [162,163]. Exercise interventions have documented effects on survival, IGF-1, natural killer cell activity, and
sex hormones [164–167]. While much work remains to be done on
integrative interventions, preliminary data suggest that integrative
medicine may signiﬁcantly support a broad-spectrum approach to
cancer therapy.
5. Proposed research model
The review process for this project has revealed many potential
targets and approaches. The cross-validation activity suggests that
only a small number of targets and approaches affect other hallmarks in contrary or controversial ways. Indeed the results suggest
that the design of a broad-spectrum approach should in fact be feasible from a safety standpoint. Although considerable research will
be needed, disease relapse is a substantial and longstanding problem, so this novel model deﬁnitely warrants further investigation.
5.1. In vitro research
An array of in vitro models is available for preliminary study
of broad-spectrum formulas. One question is the suitability of
receptor-based assays versus cell-based assays. While receptorbased assays may seem more suitable for targeted therapy research,
examining the impacts of a putative agent on a molecule such as
NF-B, which is at the intersection of multiple signaling pathways
related to inﬂammation, might be advised. Cultivated cell lines are
valuable for preliminary screening of mixtures, but are, in most
respects, limited in their predictive ability. Isolated cell lines from
clinical samples are an alternative, and use of transformed cancer
cells versus non-transformed lines should be discussed. Tissue and
organ explants are another useful in vitro model.
Basic research on the properties of the natural products and
other approaches selected in the reviews needs to continue. The
pharmacology of mixtures and combinations of phytochemicals,
bioavailability, dose optimization and synergy are among the areas
in which research is needed for many phytochemicals [168,169].
However, multicomponent herbal therapies used in traditional and
alternative medicine have not received detailed analysis. Network
pharmacology could be a means of exploring these presumed synergisms, and efforts are being made to apply this approach to
the complex herbal mixtures used in traditional Chinese medicine
[170]. Studies on the pharmacokinetics of herbal extracts and phytochemicals, which often begin at the in vitro level, are also needed
[171].
In sum, given the complexity that is immediately suggested
when combinations of approaches are possible, we strongly recommend that well-coordinated, multi-faceted programs be pursued
initially to ensure that the constituent approaches that are selected
are well-characterized using in vitro models, and that delivery
methods that are selected for in vivo work receive careful evaluation before animal research is undertaken.
5.2. In vivo research
Multiple in vivo models for further study of broad-spectrum
approaches are also available. Two obvious choices are animal
tumor models and human tumor xenografts implanted in athymic
mice. While human tumor xenografts have the advantage in predicting effects of agents on human cancer cells, animal tumors
offer some interesting choices for chemoprevention studies, since
several are induced by exposure to various chemicals. The rodent
tumors are questionable, however, in their ability to predict human
responses to antitumor therapy. Differences in immunity are one
consideration, most obviously with athymic mice but also with
other animals. Many other differences are known. Rodents and

humans, for instance, differ signiﬁcantly in their blood levels of
soy isoﬂavones after these are administered through a variety of
dietary and experimental routes [172]. Isoﬂavone levels in rodent
blood 20–150 times those in humans after similar oral intake have
been observed, raising questions about the suitability of animals
for prediction of phytochemical effects in humans.
Additionally, as shown in different preclinical mouse models,
immune and inﬂammatory responses to cancer differ in young
and old individuals, and many cancer treatments are likely to
be less effective at older ages. Combination treatment including
immunotherapeutic approaches may be most suitable for older
animals. Therefore, there is a strong argument for testing and optimizing combination treatments in suitable model systems before
attempting to apply them to cancer patients. The US National Cancer Institute Mouse Models of Human Cancer Consortium [173]
has tried to provide the scientiﬁc community with accurate, reproducible models of human cancers that can be used in translational
and preclinical studies. Such improved models could be of great
importance for developing combination treatment strategies. Companion animals, such as dogs and cats, which experience several
tumors analogous to human cancers, can also act as comparative
models for human tumors [174].
5.3. Clinical trials
Keeping in mind that a broad-spectrum approach may be used
not only by itself, but also as adjuvant therapy with conventional agents, there are numerous potential settings for clinical
trials, either for proof of principle or therapeutic goals. Preliminary studies could include metabolomic studies to identify
metabolites of dietary interventions, or the pharmacokinetics and
pharmacodynamics of phytochemical agents. A variety of settings
can be contemplated for clinical trials. One period during which
a broad-spectrum approach may be particularly appropriate is
the perioperative period. Murine data demonstrate that tumor
growth accelerates after surgery; there are also numerous anecdotal reports regarding cancer patients in whom rapid growth of
metastatic tumors has been noted after surgery [175–180]. Further,
there is reasonable human evidence that colon or rectal resection
results in signiﬁcant increases in the plasma levels of numerous
proangiogenic proteins after surgery [181–184]. This period is not
generally used for chemotherapy administration because of fears
of impaired wound healing, but the above ﬁndings provide the
rationale and motivation for systemically administering selected
anticancer agents perioperatively.
Several non-standard chemotherapy agents, including phytochemicals, have been administered perioperatively in small studies
[185–187]. These agents upregulate immune function via nonspeciﬁc mechanisms. A Phase I trial assessing the combination of EGCG
and silibinin in colorectal cancer is underway, with both agents
given orally before and after surgery [188–190]. Such trials represent an innovative approach to clinical assessment of natural
products that can be carried out within a restricted time.
Although clinical trials of phytochemicals and plant extracts
in cancer are limited compared to those with conventional
chemotherapy, they are by no means lacking. Russo et al. [58]
review nearly 50 ongoing and completed trials of phytochemicals and extracts in cancer prevention and therapy, noting that
even though clinical research is still limited, preliminary results are
promising. Most of the 50 studies took place in the United States,
and most included a single phytochemical or single-herb extract.
Nearly 3000 controlled trials of Chinese traditional medicine, 90%
concerning herbals, were reviewed by Li et al. [191]. Only 16%
of traditional medicine trials in this review reported use of adequate methods of randomization, and only a very small percentage
reported study blinding, although quality of studies improved
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through time. Most Chinese herbal formulas contain multiple herbs
and are aimed at many targets.
The design and execution of clinical trials of natural chemicals
from plants and foods, however, has been challenging worldwide.
An herbal products extension of the Consolidated Standards of
Reporting Trials (CONSORT) randomized trial reporting guideline
has been published to help improve herbal trial reporting [192].
A review of published studies of Panax ginseng, which is common
in Chinese formulas but has been studied globally for many conditions, found that only 48% of them reported CONSORT-suggested
items, and only 39% reported items from the herbal products extension [193], although these study designs also improved over time.
5.4. Translational considerations
Assuming that translational research work will involve a substantial combination of therapeutic agents such as those proposed
in Table 2 as a starting point, a ﬁrst step would be the selection of
speciﬁc targets and approaches for preliminary study. To achieve a
truly broad-spectrum effect, one strategy might be to use small
doses of every approach that lacks signiﬁcant contrary interferences. While such a mixture might be made up and applied to
cell lines, it could be questioned whether the concentrations that
could be achieved in the cells would be physiologically relevant,
especially given the low bioavailability of many phytochemicals.
Most in vitro work on single phytochemicals, however, has actually
been conducted at high concentrations that are not achievable in
humans. The pharmacokinetics and pharmacodynamics of phytochemicals are complex and many are not yet well known, although
progress is being made on some agents [194]. Another method
to narrow the number of phytochemicals that need to be in an
agent might be to select the phytochemicals that are most widely
represented across hallmarks, such as curcumin and resveratrol,
and analyze combinations of these agents. Some of the selected
approaches, e.g. silibinin, appear to have favorable pharmacokinetics [195]. Other phytochemicals with favorable pharmacokinetics
could also be considered for inclusion in a broad-spectrum agent,
such as phenethyl isothiocyanate [196]. Research is also urgently
needed on the question of the stability of phytochemicals as well
as synthetic compounds in mixtures.
Alternative approaches to the question of bioavailability are
being explored, especially with the polyphenols. One of the main
issues with these compounds, which include quercetin, green tea
catechins, curcumin and others, is ensuring that circulating doses of
aglycones (one of the active forms of these molecules) are sufﬁcient
for activity. After oral supplementation of food-grade molecules at
doses safe for humans (200–500 mg/day), only conjugated forms
are found in the bloodstream. As an example, quercetin is not
found in the plasma as aglycone or as the parent glycosides: at
the doses usually employed in intervention studies, it would be
found exclusively as methyl, sulfate or glucuronic acid conjugates
[197]. This observation discloses a paradox common to many biologically active phytochemicals: if free aglycones are absent in vivo
after a dietary intake or supplementation with high doses, how can
we explain the high biological activity of these molecules, largely
described in vitro?
Two main hypotheses can be considered. First, conjugated forms
of some ﬂavonoids (e.g. quercetin) may be biologically active. Second, after cellular uptake, these metabolites may be de-conjugated,
regenerating the free aglycones. To sustain these hypotheses, key
issues need to be addressed, such as the efﬁcacy of mechanisms
of uptake of polyphenol metabolites and the substrate speciﬁcity
of each metabolite, which is largely unknown. The use of pure
compounds tested in vitro may shed light on these questions. Alternatively, pharmacological doses (2–4 g/day) administered orally
[198] may saturate the metabolic pathways of conjugation [199].
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Efforts are being made, however, to improve bioavailability of these
agents, such as microspheres [200], liposomes [201] and nanoparticles [202]. An additional complication is that individuals may
vary in their absorption, distribution, metabolism and elimination
of phytochemicals, based in some instances on genetic variability
[203], dietary habits [204] and potentially on intestinal microbiota
[205].
Considerations of quality control are essential along the spectrum of research from in vitro studies to clinical trials. Good
agricultural practice, correct botanical identiﬁcation and good
manufacturing practice are mandatory to prevent adulteration,
contamination and toxicity [206]. The example of PC-SPES, a
botanical cancer remedy that was found to contain indomethacin,
warfarin and synthetic estrogens, leading to its withdrawal from
the market in 2002 resulted in greater awareness of the need for a
strict approach to quality control [207].
6. Implementation of broad-spectrum research agenda
A variety of practical considerations come into play in translating the proposed research model into a developmental program.
These include regulatory considerations, intellectual property, clinical considerations and funding.
6.1. Regulatory considerations
Research on the broad-spectrum model must be undertaken
with regulatory constraints in mind. Laws controlling herbal
medicines, which would likely apply to the broad-spectrum
approach, typically have regulatory paths for herbal or traditional
medicine products that differ from those for prescription drugs.
Regulations relevant to traditional Chinese herbal medicines, perhaps the closest model for the proposed broad-spectrum approach,
are reviewed by Fan et al. [208]. A few examples of national regulations regarding herbal medicines, traditional medicines and natural
product drugs follow.
The United States has perhaps the most challenging regulations
for drug approval, and regulations for mixtures are particularly
complex. Some multicomponent formulas have nevertheless been
tested in clinical trials in the US [209,210], but are still being sold
only as dietary supplements, without labeling for use in malignancy. The designation of the Botanical Drugs category may offer
opportunities to broad-spectrum agents. A recent court decision
declaring natural products unpatentable under US law adds an
interesting wrinkle to the regulatory framework [211]. In Canada,
development as a high-risk Natural Health Product could be considered [212]. China has a variety of regulatory categories that
could be used for multicomponent natural product therapeutics
[213]. The relevance of Chinese regulations for multi-targeted drugs
has been explored [214]. In the European Union, the Marketing
Authorization scheme for conventional drugs would need to be
used, rather than the Traditional Herbal Regulation Scheme [215],
increasing the challenge for developmental research. In India it is
likely that New Chemical Entity approval would be required [216],
since use in cancer would likely be considered beyond traditional
herbal medicine usage. Japan allows herbal medicines to be registered as prescription or over-the-counter drugs [208]; prescription
licensing appears likely for an anticancer therapeutic. A variety of
regulations exist in other countries, which are beyond the scope of
this paper, and which would need to be explored individually. We
expect that working under these strict regulations will be difﬁcult,
but we do not see it as impossible.
An additional regulatory consideration is the acceptability of the
broad-spectrum approach to institutionally-based ethical review
boards needed for clinical research. In institutions located in
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countries in which multi-component herbal formulas are typical
of traditional medicine, ethical approval of such formulas is common, as suggested by the large numbers of clinical studies on
traditional Chinese herbal medicine [191] and Japanese Kampo
medicine [217]. Trials with multi-component formulas and natural products have been conducted under other regulatory schemes
as well. For instance, Phase I and Phase Ib studies of BZL101, an
extract of Scutellaria barbata in metastatic breast cancer have been
conducted in the United States [218,219]. A 4-herb combination
originating in traditional Chinese medicine, PHY906, has been the
subject of a Phase I trial as an adjunct to capecitabine in advanced
pancreatic cancer, also in the United States [220]. In general, provision of sufﬁcient preclinical and drug formulation information,
review of prior clinical studies, and possession of appropriate
approvals from national-level agencies will facilitate approval of
study protocols.
6.2. Intellectual property
Herbs and natural products in their native forms do not have
intellectual property protection, which should help in developing a
low-cost, broad-spectrum formulation. Speciﬁed extracts and individual phytochemicals may have intellectual property of various
types. Researchers could pursue intellectual property protection
for speciﬁc broad-spectrum therapeutics they develop, as well as
licensing to a pharmaceutical company with sufﬁcient resources
to support development and testing of the agent. Herbal extracts
of some complexity have received patent or trademark status,
and have been granted drug approval even in the United States,
Examples include a mixture of green tea polyphenols known as
Polyphenon E and sold as the patented drug sinecatechins for
genital warts [221], and crofelemer, an extract from the South
American plant Croton lechleri, approved for HIV-induced diarrhea [222]. The complexities of natural product patenting are
beyond the scope of this paper but are covered in depth elsewhere
[223].
6.3. Clinical considerations for a multi-component natural
product therapeutic
Based on current clinical experience with natural products
administered together with conventional drugs, one may anticipate
potential concerns with broad-spectrum therapeutics that would
be administered jointly with conventional therapies. A primary
concern is the interactions between drugs and herbs or phytochemicals, including both pharmacokinetic and pharmacodynamic
interactions [224]. This has been of special concern in oncology
due to the life-threatening consequences of lowered blood levels
of drugs, and the potential for severe side effects when blood levels of a drug are increased or actions of herbal products reinforce
those of conventional agents. Antiplatelet activity is common in
natural products [225], and may aggravate clinical consequences
in patients with thrombocytopenia due to chemotherapy or other
drugs [226]. Several other examples of negative interactions are
known or suspected. St John’s wort (used for depression) contains the strong cytochrome P450 3A4 inducer hyperforin, which
is known to reduce blood levels of many drugs, including irinotecan [227]. Green tea, which is often taken in high doses by
cancer patients, has potential interactions with sunitinib [228],
with hepatotoxic drugs [229], and with bortezomib. On the other
hand, positive interactions have been observed with green tea and
erlotinib, a combination now in clinical trials [230]. Curcumin is
one of several natural products that act as chemosensitizers and
radiosensitizers for several tumors, while protecting normal tissues [231]. The ability of herbs and other natural products to relieve
treatment-related side effects should not be overlooked [232,233].

Furthermore, many natural products possess antioxidant activity. The role of oxidation in cancer progression and treatment is
controversial [234]. Oxidative stress is increased in late-stage disease [235], which suggests that suppression would be beneﬁcial.
Antioxidants may relieve some adverse treatment effects caused
by the reactive oxygen species generated by many chemotherapy
drugs, but data on this point are not conclusive [236,237]. Randomized trials of antioxidant supplements given with chemotherapy
do not ﬁnd evidence of reduced efﬁcacy, but research with better study design and larger sample size should be conducted [238].
Additionally, some natural antioxidants, including the polyphenols,
manifest pro-oxidant properties in cancer cells, due to interactions
with metal ions, which contribute to anticancer effects [239]. This
pro-oxidant effect has been hypothesized to underlie the broadly
multi-targeted actions of polyphenols such as curcumin and EGCG
[240]. However, activity of most chemotherapy drugs depends on
generation of ROS which should not be abrogated. Additionally,
some oxidative metabolites may act as signaling molecules with
anticancer activity [241]. Further, intracellular antioxidants may
contribute to drug resistance [242]. Our understanding of the interactions of antioxidants and cancer thus continues to develop [243].
Patients are often warned not to supplement with antioxidants
during treatment.
6.4. Funding
Development of new clinical agents that could be approved by
regulatory agencies is an expensive endeavor. A recent economic
model of drug discovery and development in the United States
used industry-appropriate assumptions to estimate that the fully
capitalized cost of a typical new single-molecule drug developed
is now approximately $1.8 billion, 63% of which is attributable
to clinical development (Phase I–III studies) [244]. The details
of such estimates are beyond the scope of this paper, but the
ﬁnancial challenges are clear. It is our contention that a multicomponent broad-spectrum therapeutic approach is needed to
complement and balance the current drug discovery paradigm,
which focuses on narrowly scoped approaches and singular molecular targets, including targeted therapies, immunotherapy, “one
mouse-one patient” avatars that identify personalized therapeutic regimens by implanting patients’ tumors into mice [245,246]
and a variety of other approaches. Such an approach could be
expensive to develop, and could face similar costs for trials
and approval. However, a broad-spectrum approach could be
aimed at wide applicability among many cancer types and subtypes. Thus, initial investment could be more easily recovered
than is the case with narrowly-focused target therapies, since
it would have utility across a large group of patients. Whether
the development of the broad-spectrum approach should be
carried forward by governments, for-proﬁt pharmaceutical companies or even non-proﬁt pharmaceutical companies is an open
question.
6.5. Importance for low- and middle-income countries
The possibility that a broad-spectrum approach could be developed that is both effective and inexpensive is an important
consideration, especially in low- and middle-income countries. One
of the cost components of drug development is the cost of target
identiﬁcation and validation. However, in the Halifax Project the
strategic list of targets that has been developed has been drawn
from the open literature, so individual laboratories or nations
that are interested in developing a multi-component therapeutic
approach can use this information as a starting point (i.e., as a basis
for rationally selecting an array of targets).
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7. Summary and conclusions
In spite of the importance of targeted therapies now used in
treatment and currently in development, it is clear that most
cancers cannot be successfully addressed solely with singletarget therapies. The history of cancer treatment has taught us
the importance of drug resistance, stemming ultimately from
genetic heterogeneity in cancers. Our therapeutic tool kit now
includes a large array of cytotoxic chemotherapies, molecular target drugs, immunotherapies and hormonal therapies. A major
paradigm in cancer research, in response to the advances in analysis of the cancer genome, is the development of increasingly
targeted therapies. Examples illustrating the vigor of research
and development in this area are several targeted therapies that
have received approval in 2013–2014 by the US FDA, including
ceritinib (anaplastic lymphoma kinase inhibitor), ramucirumab
(VEGFR2 blocker), ibrutinib (Bruton’s tyrosine kinase inhibitor),
trametinib (MEK inhibitor) and dabrafenib (B-Raf inhibitor)
[244].
At the same time there is an increasing awareness of a need to
develop a therapeutic approach to address the genetic heterogeneity within tumors. Even within this group of newly approved agents,
the combination of trametinib and dabrafenib was approved for
joint use in 2014, due to the rapid (6–7 months) development of
resistance to the sole use of B-Raf inhibitors. The emergence of the
concept of multiple hallmarks of cancer [27], the nine pathways of
progression [3] the listing of 138 driver genes [6] and the recognition of the importance of network pharmacology [51] all attest
to the importance of this issue. A recent review similarly suggests
combining antiinﬂammatory and antioxidant treatment in longterm maintenance therapy of cancer [247]. It is the contention of the
Halifax Project that a broad-spectrum approach to cancer prophylaxis and treatment (i.e., simultaneously attacking many targets) is
a strategic and promising response to our increasing understanding
of the signiﬁcance of genetic heterogeneity.
Although current drugs have notably increased initial responsiveness to treatment in comparison to traditional approaches to
chemotherapy, there remain situations in which a broad-spectrum
approach could make real contributions. Some examples include
use as follow-up to conventional treatment; for rare cancers; for
patients who do not tolerate conventional treatment; for earlystage disease, when aggressive treatment should be avoided; and
in hospice and palliative care. If signiﬁcant interactions with treatments can be avoided, it might even be possible to use such
approaches in conjunction with targeted therapies and other treatments.
What are the implications of this broad-spectrum strategy
for current clinical practice? First, clinicians should realize that
this paper presents a developmental research program, not clinical guidelines. Use of uninformed selections of phytochemical or
botanical extracts in poorly-deﬁned clinical situations is unlikely
to deliver positive results. Further, as noted above, concerns with
interactions of natural products with conventional treatments
should be kept in mind. That said, lifestyle therapies appear to
affect multiple molecular targets and to improve the health of
cancer patients in a variety of ways, and integrative lifestyle modiﬁcations should be assessed as a health-promoting foundation
for use of broad-spectrum therapeutics [3,149]. Clinical trials are
now deﬁning beneﬁcial impacts of natural products [248]. The
positive implications of dietary therapies for improvement of the
metabolic hallmarks of inﬂammation, dysregulated metabolism,
genomic instability and immune system evasion should be kept
in mind [249,250]. Clinicians choosing to use natural product supplements should attend to product quality and be familiar with
advances in the formulation of poorly absorbed polyphenols and
other phytochemicals [200–202].
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The development of the broad-spectrum approach is not without cost. A primary need is further development of preclinical
models for testing of combinatorial therapies, including study of
the stability, pharmacodynamics and pharmacokinetics of agents
comprising multiple phytochemicals and other molecules. While
some of the targets and approaches recommended in these reviews
are well-known and have been the subject of multiple reviews,
others are still only promising leads and may need much better characterization before being adopted as constituents in such
an approach. For example, among approaches, curcumin, genistein, resveratrol and EGCG boast a wealth of fundamental research,
whereas other approaches such as tripterine, oleanoic acid and
withaferin A will require additional basic research. Targets are also
in need of more basic research, especially in replicative immortality
and in dysregulated metabolism, a ﬁeld in which studies of relevant targets are just beginning. The approaches analyzed in these
areas are similarly only in the most preliminary stages of research.
All the hallmarks, however, include targets and approaches that
need substantial basic research. Determining how many of the suggested targets should be included in a broad-spectrum approach
is also a question that needs substantial research. Supporting
these areas of basic research should be an initial goal of funding
efforts.
The pharmacology of mixtures of natural products is another
area in which basic research is most relevant to the goals of this
project. There is certainly a body of research on complex mixtures of natural products [210,214,217,218,220]. A recent study
suggested that EGCG lowers the concentration of curcumin needed
to reduce proliferation and induce apoptosis in uterine leiomyosarcoma cells [251]. Traditional Chinese medicine formulas have also
been subjected to extensive pharmacological testing [252,253].
However, much remains to be done in quantitative optimization
of formulas as well as in selection of optimal natural product
extracts or phytochemicals. And although this effort emphasized
phytochemicals, it is also important and relevant to study deﬁned
botanical and food extracts. Standardized black raspberry extract,
for instance, has produced positive results in human trials on
apoptosis, angiogenesis and several speciﬁc targets selected in
the project [254]. Aged garlic extract [255] increased immunity
in advanced cancer patients, and lyophilized strawberries [256]
improved premalignant esophageal lesions. Deﬁned herbal extracts
such as PHY 906 and BZL101 mentioned above have demonstrated preliminary clinical antitumor activity [219,220]. Stability
and pharmacokinetic properties of complex mixtures are another
critical research need, as are proper methods of quality control
[257].
The development of complex natural product agents appears
ripe for cross-disciplinary approaches as well as attention to the
process of translational research. Natural products research, in fact,
has long been nurtured most successfully in multidisciplinary and
collaborative working groups [258], and the teams that authored
the reviews in this special issue were notably interdisciplinary
themselves. In view of the challenges as well as the unique opportunities this new concept entails, scientists wishing to take part in
the development of broad-spectrum approaches to cancer would
do well to commit themselves to a set of new attitudes and
skills. Laboratories and grant proposals have achieved success typically based on highly focused exploration of a small intellectual
niche. The broad-spectrum approach upends this paradigm. Building linkages with laboratories across campus, or even with the
department down the hall, is not always encouraged in academic
institutions. But this challenge is not insurmountable, and institutions and granting agencies have successfully mounted efforts
that embrace, for instance, natural product development “from the
ﬁeld to the clinic” [259,260]. At the same time, integrative oncology centers globally employ broad-spectrum clinical approaches
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involving therapies ranging from natural products to meditation in
the service of patient needs [261]. There is thus no need to start
from absolute zero in building the cross-disciplinary alliances we
project will be needed for this effort.
What will be needed is a core group of scientists willing to
become advocates for this approach. Advocacy must take place
within academic institutions, as institutional silos, perhaps reluctantly, open their doors to collaboration. Institutional review
boards and grant ofﬁces may need education in the concept of the
broad-spectrum approach. Advocacy must take place at higher levels as well. National funding agencies and charitable foundations
that currently support cancer research need to heed these recommendations and shift quickly to embrace the rationale for this
interdisciplinary team-based approach. Grant review committees
may need to confront established interests promoting competing
studies with more familiar narrow aims. Creativity in funding initial
research efforts will be needed. International agencies interested in
addressing the growth of cancer in low to middle income countries
might be convinced that broad-spectrum approaches could result
in lower-cost and often more culturally acceptable therapeutic
tools for these areas.
Now is the time to begin the work of advocating for broadspectrum therapeutic approaches in cancer. Scientists need to seize
the opportunities provided by the unique information provided in
this special issue to expand their acquaintance with this model
– and perhaps with the scientists themselves who are already
involved in this effort. Scientists and clinicians alike should become
advocates to their institutions, to funding sources and to the wider
public. This dimension of cancer biology and therapy has too much
potential to allow it to languish. At the same time, clinical challenges mount, despite the emergence of new targeted therapies. We
look forward to seeing concentrated energy and intellect focused
on this new approach, and to seeing it yield signiﬁcant therapeutic
beneﬁts in the future.
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